ID,Description,GeneRatio,BgRatio,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-112316,Neuronal System,43/265,410/11091,1.275586911591023e-16,9.592413575164494e-14,8.338310232610795e-14,6804/7277/23415/5582/10382/9379/3746/6853/2901/10369/43/10815/4137/4128/3761/57576/50944/57497/3359/93107/1141/774/1103/2902/58512/3777/1741/6572/7102/80852/8224/3765/3745/7280/56666/55799/51305/3748/9066/81033/3768/22941/2892,43
R-HSA-112315,Transmission across Chemical Synapses,28/265,270/11091,5.202110403961947e-11,1.9559935118896923e-8,1.7002687162422998e-8,6804/7277/5582/10382/6853/2901/10369/43/10815/4137/4128/3761/57576/3359/1141/774/1103/2902/1741/6572/7102/80852/8224/3765/7280/55799/3768/2892,28
R-HSA-373760,L1CAM interactions,18/265,119/11091,3.8562122838318006e-10,9.666238791471714e-8,8.40248360792824e-8,1463/10752/7277/57731/10382/3673/286/1641/6900/23114/1741/6326/4897/3897/2596/7280/55800/4684,18
R-HSA-5576891,Cardiac conduction,15/265,132/11091,5.62351762020433e-7,1.057221312598414e-4,9.190011689860235e-5,775/6543/3761/30818/3777/6326/1482/491/4881/6547/55800/25937/51305/478/3768,15
R-HSA-1971475,A tetrasaccharide linker sequence is required for GAG synthesis,7/265,26/11091,1.8312286765715175e-6,2.4588983126028256e-4,2.1374242051040802e-4,1463/6383/63827/633/10675/2719/27087,7
R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,18/265,205/11091,1.9618869515448078e-6,2.4588983126028256e-4,2.1374242051040802e-4,7277/5582/10382/2901/10369/4137/3761/57576/3359/1141/2902/1741/7102/80852/3765/7280/3768/2892,18
R-HSA-1474244,Extracellular matrix organization,22/265,300/11091,2.946656885697554e-6,3.165551397206515e-4,2.751690114313054e-4,5054/1463/3910/170690/3673/6383/4327/10893/63827/1303/633/10319/50859/1756/4318/3914/22801/64386/1297/655/3679/4684,22
R-HSA-3560783,"Defective B4GALT7 causes EDS, progeroid type",6/265,20/11091,5.142223473784578e-6,3.866952052286003e-4,3.361390291810761e-4,1463/6383/63827/633/10675/2719,6
R-HSA-3560801,Defective B3GAT3 causes JDSSDHD,6/265,20/11091,5.142223473784578e-6,3.866952052286003e-4,3.361390291810761e-4,1463/6383/63827/633/10675/2719,6
R-HSA-4420332,Defective B3GALT6 causes EDSP2 and SEMDJL1,6/265,20/11091,5.142223473784578e-6,3.866952052286003e-4,3.361390291810761e-4,1463/6383/63827/633/10675/2719,6
R-HSA-445095,Interaction between L1 and Ankyrins,7/265,31/11091,6.608466104509282e-6,4.5177877369008906e-4,3.927136316650971e-4,57731/286/23114/6326/4897/3897/55800,7
R-HSA-397014,Muscle contraction,17/265,205/11091,8.209077023647379e-6,4.991737792096501e-4,4.339122576836405e-4,775/6543/1756/3761/8913/30818/3777/6326/1482/491/4881/6547/55800/25937/51305/478/3768,17
R-HSA-3781865,Diseases of glycosylation,14/265,144/11091,8.629333949102995e-6,4.991737792096501e-4,4.339122576836405e-4,1463/170691/170690/6383/3955/63827/170689/633/10675/4585/2719/79875/10418/10417,14
R-HSA-1296071,Potassium Channels,11/265,103/11091,3.3599499689845065e-5,0.0018047731261973921,0.0015688187449168262,23415/3746/3761/93107/3777/3765/3745/51305/3748/81033/3768,11
R-HSA-6794362,Protein-protein interactions at synapses,10/265,86/11091,3.665179488115285e-5,0.001837476650041796,0.001597246640083924,6804/9379/50944/57497/2902/58512/1741/9066/22941/2892,10
R-HSA-6794361,Neurexins and neuroligins,8/265,55/11091,4.398317723522003e-5,0.0020672093300553415,0.0017969442804652398,6804/9379/50944/2902/58512/1741/9066/22941,8
R-HSA-419037,NCAM1 interactions,7/265,42/11091,5.4162920688194575e-5,0.0023930189112086634,0.002080157816154227,1463/775/6900/8913/2674/1297/4684,7
R-HSA-1638091,Heparan sulfate/heparin (HS-GAG) metabolism,8/265,57/11091,5.727970798105843e-5,0.0023930189112086634,0.002080157816154227,1463/6383/63827/633/266722/10675/2719/27087,8
R-HSA-3000178,ECM proteoglycans,9/265,76/11091,7.792703475485427e-5,0.0030842700071394957,0.00268103537854651,5054/1463/3910/3673/63827/633/1297/3679/4684,9
R-HSA-2022923,Dermatan sulfate biosynthesis,4/265,11/11091,9.210894700757953e-5,0.0034632964074849905,0.0030105082153529944,1463/63827/633/10675,4
R-HSA-375165,NCAM signaling for neurite out-growth,8/265,63/11091,1.1864128853301835e-4,0.004248488046515705,0.0036930446205014735,1463/57731/775/6900/8913/2674/1297/4684,8
R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,7/265,50/11091,1.703955748573602e-4,0.005824430558760675,0.005062949855809603,1463/6383/63827/633/10675/2719/27087,7
R-HSA-112310,Neurotransmitter release cycle,7/265,51/11091,1.9352961977254357e-4,0.006327577133432729,0.005500315509324924,6804/6853/10815/4128/1103/6572/8224,7
R-HSA-5083635,Defective B3GALTL causes PpS,6/265,37/11091,2.1928459753186197e-4,0.006810150817032764,0.005919797952655861,170691/170690/170689/79875/10418/10417,6
R-HSA-3906995,Diseases associated with O-glycosylation of proteins,8/265,69/11091,2.2640129045986584e-4,0.006810150817032764,0.005919797952655861,170691/170690/3955/170689/4585/79875/10418/10417,8
R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,6/265,38/11091,2.552459830536986e-4,0.007352797019996414,0.00639149908933059,170691/170690/170689/79875/10418/10417,6
R-HSA-2024101,CS/DS degradation,4/265,14/11091,2.639967015158287e-4,0.007352797019996414,0.00639149908933059,1463/63827/633/10675,4
R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,6/265,41/11091,3.915431528386923e-4,0.010153118997748158,0.008825709543115352,1463/6383/63827/633/10675/2719,6
R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,6/265,41/11091,3.915431528386923e-4,0.010153118997748158,0.008825709543115352,7277/10382/57576/2902/1741/7280,6
R-HSA-375280,Amine ligand-binding receptors,6/265,42/11091,4.477731915304412e-4,0.01122418133436306,0.009756742173347509,1131/1128/1813/3357/3352/1129,6
R-HSA-1296072,Voltage gated Potassium channels,6/265,43/11091,5.101056734581854e-4,0.01237417633679211,0.010756387885145439,23415/3746/93107/3745/3748/81033,6
R-HSA-264642,Acetylcholine Neurotransmitter Release Cycle,4/265,17/11091,5.931639419022838e-4,0.013516948009409618,0.01174975463863854,6804/10815/1103/6572,4
R-HSA-416993,Trafficking of GluR2-containing AMPA receptors,4/265,17/11091,5.931639419022838e-4,0.013516948009409618,0.01174975463863854,5582/7102/80852/2892,4
R-HSA-3000157,Laminin interactions,5/265,30/11091,6.548605545726679e-4,0.014483974618783714,0.01259035307707823,3910/3673/10319/3914/3679,5
R-HSA-181429,Serotonin Neurotransmitter Release Cycle,4/265,18/11091,7.484160642574615e-4,0.015153489637571507,0.013172336317093934,6804/6853/10815/8224,4
R-HSA-190840,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,4/265,18/11091,7.484160642574615e-4,0.015153489637571507,0.013172336317093934,7277/10382/2697/7280,4
R-HSA-399719,Trafficking of AMPA receptors,5/265,31/11091,7.657348487070708e-4,0.015153489637571507,0.013172336317093934,5582/10369/7102/80852/2892,5
R-HSA-399721,"Glutamate binding, activation of AMPA receptors and synaptic plasticity",5/265,31/11091,7.657348487070708e-4,0.015153489637571507,0.013172336317093934,5582/10369/7102/80852/2892,5
R-HSA-190872,Transport of connexons to the plasma membrane,4/265,19/11091,9.303273020688035e-4,0.017490153278893507,0.015203506699598081,7277/10382/2697/7280,4
R-HSA-5576886,Phase 4 - resting membrane potential,4/265,19/11091,9.303273020688035e-4,0.017490153278893507,0.015203506699598081,3761/3777/51305/3768,4
R-HSA-5668914,Diseases of metabolism,15/265,250/11091,9.818492923735218e-4,0.018008552874753374,0.015654131208317254,1463/170691/170690/6383/3955/63827/170689/633/4128/10675/4585/2719/79875/10418/10417,15
R-HSA-2022870,Chondroitin sulfate biosynthesis,4/265,20/11091,0.0011412546720538474,0.02043389317582127,0.017762384745499734,1463/63827/633/10675,4
R-HSA-9662360,Sensory processing of sound by inner hair cells of the cochlea,7/265,69/11091,0.0012522634942379114,0.021900049945742076,0.019036857525624066,6804/6855/6853/8927/9381/491/494513,7
R-HSA-8849932,Synaptic adhesion-like molecules,4/265,21/11091,0.0013835543601141542,0.023360441317747314,0.020306318670662207,57497/2902/1741/2892,4
R-HSA-5173105,O-linked glycosylation,9/265,112/11091,0.0014261380988069075,0.023360441317747314,0.020306318670662207,170691/170690/170689/79623/4585/79875/10418/442117/10417,9
R-HSA-70635,Urea cycle,3/265,10/11091,0.0014289631657132664,0.023360441317747314,0.020306318670662207,162417/445/1373,3
R-HSA-442755,Activation of NMDA receptors and postsynaptic events,8/265,93/11091,0.001686368818369255,0.02698190109390808,0.02345431212110431,7277/10382/4137/57576/2902/1741/7280/2892,8
R-HSA-1474228,Degradation of the extracellular matrix,10/265,140/11091,0.0019254954170942174,0.030166094867809405,0.02622220732490152,170690/4327/10893/63827/1303/50859/4318/3914/64386/1297,10
R-HSA-212676,Dopamine Neurotransmitter Release Cycle,4/265,23/11091,0.00197163637329511,0.03025858270852903,0.026302603390252702,6804/6853/10815/8224,4
R-HSA-9659379,Sensory processing of sound,7/265,76/11091,0.002203234383344548,0.03275286376325405,0.028470784430264233,6804/6855/6853/8927/9381/491/494513,7
R-HSA-9031628,NGF-stimulated transcription,5/265,39/11091,0.002221271345646219,0.03275286376325405,0.028470784430264233,7425/2353/429/23237/6446,5
R-HSA-112308,Presynaptic depolarization and calcium channel opening,3/265,12/11091,0.002528519727863043,0.03656628529525016,0.03178564273285324,10369/774/55799,3
R-HSA-3000171,Non-integrin membrane-ECM interactions,6/265,59/11091,0.0027430189189783143,0.03891981560512627,0.0338314746511526,3910/3673/6383/10319/1756/3914,6
R-HSA-1630316,Glycosaminoglycan metabolism,9/265,126/11091,0.0032035784061721115,0.04461279558224866,0.038780159653662404,1463/6383/63827/633/266722/10675/2719/27087/3037,9
R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",4/265,27/11091,0.0036258268534593244,0.04957494170548021,0.04309355934924862,5054/79365/8553/56938,4
R-HSA-975634,Retinoid metabolism and transport,5/265,44/11091,0.0038034126348604714,0.051074398239554904,0.04439697831293897,4035/6383/8644/2719/1645,5
R-HSA-418359,Reduction of cytosolic Ca++ levels,3/265,14/11091,0.004038180016285461,0.05146968427536724,0.04474058501540181,6543/491/6547,3
R-HSA-5578768,Physiological factors,3/265,14/11091,0.004038180016285461,0.05146968427536724,0.04474058501540181,1482/4881/25937,3
R-HSA-5682910,LGI-ADAM interactions,3/265,14/11091,0.004038180016285461,0.05146968427536724,0.04474058501540181,6804/10369/203190,3
R-HSA-8957275,Post-translational protein phosphorylation,8/265,108/11091,0.0042939735505795155,0.05381780183392993,0.0467817118405242,29106/7425/718/6383/7857/2719/1114/7018,8
R-HSA-9619483,Activation of AMPK downstream of NMDARs,4/265,29/11091,0.004727133192240234,0.058275478042043534,0.05065659555446394,7277/10382/4137/7280,4
R-HSA-8874081,MET activates PTK2 signaling,4/265,30/11091,0.005353636674958331,0.06493443192852685,0.05644496392443334,3910/3673/10319/3914,4
R-HSA-6806667,Metabolism of fat-soluble vitamins,5/265,48/11091,0.005551316057753384,0.06626332818143722,0.05760012150150129,4035/6383/8644/2719/1645,5
R-HSA-196807,Nicotinate metabolism,4/265,31/11091,0.00603332583440296,0.07089157855423478,0.06162327867046445,952/4907/23057/54981,4
R-HSA-1592389,Activation of Matrix Metalloproteinases,4/265,33/11091,0.0075597099241229305,0.0874600286606222,0.07602558482397312,10893/50859/4318/64386,4
R-HSA-196854,Metabolism of vitamins and cofactors,11/265,198/11091,0.007997158203946217,0.09111913589950842,0.07920630374243383,952/4907/4035/6383/160428/23057/8644/6472/2719/54981/1645,11
R-HSA-181430,Norepinephrine Neurotransmitter Release Cycle,3/265,18/11091,0.008436595973742246,0.09469134585453984,0.08231148624813724,6804/10815/4128,3
R-HSA-71387,Metabolism of carbohydrates,14/265,290/11091,0.009894790428534184,0.10942474120967216,0.09511865102352522,1463/6383/63827/633/2523/8707/266722/10675/2719/226/27087/2026/3037/8708,14
R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),8/265,125/11091,0.010164015971319353,0.11057425163228136,0.096117875509024,29106/7425/718/6383/7857/2719/1114/7018,8
R-HSA-190861,Gap junction assembly,4/265,36/11091,0.01029281597640917,0.11057425163228136,0.096117875509024,7277/10382/2697/7280,4
R-HSA-438064,Post NMDA receptor activation events,6/265,80/11091,0.012094373530390959,0.12809815344864792,0.11135071849329556,7277/10382/4137/2902/1741/7280,6
R-HSA-983189,Kinesins,5/265,59/11091,0.013139564451162052,0.1372354509343592,0.11929341409607654,7277/10382/3798/7280/547,5
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),15/265,334/11091,0.014311434973012904,0.1467660729668249,0.1275780113555407,718/1131/1128/3627/1813/3357/6387/4852/23566/2834/3352/1910/7852/4988/1129,15
R-HSA-389977,Post-chaperonin tubulin folding pathway,3/265,22/11091,0.014843677811773556,0.1467660729668249,0.1275780113555407,7277/10382/7280,3
R-HSA-438066,"Unblocking of NMDA receptors, glutamate binding and activation",3/265,22/11091,0.014843677811773556,0.1467660729668249,0.1275780113555407,2902/1741/2892,3
R-HSA-9033658,Blood group systems biosynthesis,3/265,22/11091,0.014843677811773556,0.1467660729668249,0.1275780113555407,2523/8707/8708,3
R-HSA-198725,Nuclear Events (kinase and transcription factor activation),5/265,61/11091,0.015027909067081804,0.1467660729668249,0.1275780113555407,7425/2353/429/23237/6446,5
R-HSA-8875878,MET promotes cell motility,4/265,41/11091,0.016132096432357145,0.1555299553478535,0.1351961118015356,3910/3673/10319/3914,4
R-HSA-166663,Initial triggering of complement,3/265,23/11091,0.016774484027545344,0.15967610112296327,0.13880019428521864,718/716/715,3
R-HSA-264876,Insulin processing,3/265,25/11091,0.021038124125917733,0.19531690546531033,0.16978135259512558,6804/3800/3798,3
R-HSA-389960,Formation of tubulin folding intermediates by CCT/TriC,3/265,25/11091,0.021038124125917733,0.19531690546531033,0.16978135259512558,7277/10382/7280,3
R-HSA-112311,Neurotransmitter clearance,2/265,10/11091,0.02255113274386588,0.20431869666731498,0.17760625788130266,43/4128,2
R-HSA-1855167,Synthesis of pyrophosphates in the cytosol,2/265,10/11091,0.02255113274386588,0.20431869666731498,0.17760625788130266,55190/170685,2
R-HSA-9660826,Purinergic signaling in leishmaniasis infection,3/265,26/11091,0.023371757067860693,0.20677130958860285,0.1797382184413807,4907/718/834,3
R-HSA-9664424,Cell recruitment (pro-inflammatory response),3/265,26/11091,0.023371757067860693,0.20677130958860285,0.1797382184413807,4907/718/834,3
R-HSA-190828,Gap junction trafficking,4/265,47/11091,0.025441911731838768,0.21741270025389492,0.18898836346258224,7277/10382/2697/7280,4
R-HSA-437239,Recycling pathway of L1,4/265,47/11091,0.025441911731838768,0.21741270025389492,0.18898836346258224,7277/10382/3897/7280,4
R-HSA-977606,Regulation of Complement cascade,4/265,47/11091,0.025441911731838768,0.21741270025389492,0.18898836346258224,718/716/3426/715,4
R-HSA-400253,Circadian Clock,5/265,70/11091,0.025754777261515358,0.21761339888381515,0.18916282293791883,5054/79365/8553/56938/8204,5
R-HSA-1483191,Synthesis of PC,3/265,28/11091,0.028442574054508576,0.23248712705424404,0.2020919735451925,43/1103/64900,3
R-HSA-389957,Prefoldin mediated transfer of substrate  to CCT/TriC,3/265,28/11091,0.028442574054508576,0.23248712705424404,0.2020919735451925,7277/10382/7280,3
R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,3/265,28/11091,0.028442574054508576,0.23248712705424404,0.2020919735451925,7402/1821/25937,3
R-HSA-157858,Gap junction trafficking and regulation,4/265,49/11091,0.029133346130902297,0.23557286333804867,0.20477428350073942,7277/10382/2697/7280,4
R-HSA-6811434,COPI-dependent Golgi-to-ER retrograde traffic,6/265,99/11091,0.031133011009975935,0.2363237299655508,0.2054269825148475,7277/10382/3798/7280/547/63908,6
R-HSA-1296041,Activation of G protein gated Potassium channels,3/265,29/11091,0.03117897107707798,0.2363237299655508,0.2054269825148475,3761/3765/3768,3
R-HSA-1296059,G protein gated Potassium channels,3/265,29/11091,0.03117897107707798,0.2363237299655508,0.2054269825148475,3761/3765/3768,3
R-HSA-997272,Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits,3/265,29/11091,0.03117897107707798,0.2363237299655508,0.2054269825148475,3761/3765/3768,3
R-HSA-500792,GPCR ligand binding,18/265,468/11091,0.03178039089467791,0.2363237299655508,0.2054269825148475,718/1131/1128/3627/1813/3357/7432/6387/4852/23566/2834/3352/1910/2912/7852/4988/1129/117,18
R-HSA-1296346,Tandem pore domain potassium channels,2/265,12/11091,0.03205454847936992,0.2363237299655508,0.2054269825148475,3777/51305,2
R-HSA-390666,Serotonin receptors,2/265,12/11091,0.03205454847936992,0.2363237299655508,0.2054269825148475,3357/3352,2
R-HSA-451306,Ionotropic activity of kainate receptors,2/265,12/11091,0.03205454847936992,0.2363237299655508,0.2054269825148475,2901/1741,2
R-HSA-451308,Activation of Ca-permeable Kainate Receptor,2/265,12/11091,0.03205454847936992,0.2363237299655508,0.2054269825148475,2901/1741,2
R-HSA-6811436,COPI-independent Golgi-to-ER retrograde traffic,4/265,51/11091,0.03312630712802119,0.24154495018827288,0.20996558520005246,7277/10382/51560/7280,4
R-HSA-9833482,PKR-mediated signaling,5/265,75/11091,0.033405152685612206,0.24154495018827288,0.20996558520005246,7277/10382/57697/4137/7280,5
R-HSA-6807878,COPI-mediated anterograde transport,6/265,101/11091,0.033872562663409676,0.24155128691829988,0.20997109347181445,7277/57731/10382/286/7280/63908,6
R-HSA-418360,Platelet calcium homeostasis,3/265,30/11091,0.034048452677313545,0.24155128691829988,0.20997109347181445,6543/491/6547,3
R-HSA-2022928,HS-GAG biosynthesis,3/265,31/11091,0.0370500734104825,0.2526684754752437,0.21963483100521605,6383/266722/2719,3
R-HSA-2122948,Activated NOTCH1 Transmits Signal to the Nucleus,3/265,31/11091,0.0370500734104825,0.2526684754752437,0.21963483100521605,92737/8788/3714,3
R-HSA-9668328,Sealing of the nuclear envelope (NE) by ESCRT-III,3/265,31/11091,0.0370500734104825,0.2526684754752437,0.21963483100521605,7277/10382/7280,3
R-HSA-425561,Sodium/Calcium exchangers,2/265,13/11091,0.037295479757649,0.2526684754752437,0.21963483100521605,6543/6547,2
R-HSA-432047,Passive transport by Aquaporins,2/265,13/11091,0.037295479757649,0.2526684754752437,0.21963483100521605,358/89872,2
R-HSA-422356,Regulation of insulin secretion,5/265,78/11091,0.038606792300923114,0.25881487921827556,0.2249776595668381,6804/775/1131/6861/3745,5
R-HSA-5620924,Intraflagellar transport,4/265,54/11091,0.0396864372013631,0.25881487921827556,0.2249776595668381,7277/10382/57576/7280,4
R-HSA-389958,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,3/265,32/11091,0.04018269335492199,0.25881487921827556,0.2249776595668381,7277/10382/7280,3
R-HSA-5626467,RHO GTPases activate IQGAPs,3/265,32/11091,0.04018269335492199,0.25881487921827556,0.2249776595668381,7277/10382/7280,3
R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,3/265,32/11091,0.04018269335492199,0.25881487921827556,0.2249776595668381,118788/6850/695,3
R-HSA-8856688,Golgi-to-ER retrograde transport,7/265,133/11091,0.040267740516673194,0.25881487921827556,0.2249776595668381,7277/10382/3798/51560/7280/547/63908,7
R-HSA-166520,Signaling by NTRKs,7/265,134/11091,0.041659638797548075,0.26190608952847944,0.22766472787959932,7425/2353/429/23237/627/6446/117,7
R-HSA-166786,Creation of C4 and C2 activators,2/265,14/11091,0.04283836304787629,0.26190608952847944,0.22766472787959932,716/715,2
R-HSA-190373,FGFR1c ligand binding and activation,2/265,14/11091,0.04283836304787629,0.26190608952847944,0.22766472787959932,7049/2246,2
R-HSA-193775,Synthesis of bile acids and bile salts via 24-hydroxycholesterol,2/265,14/11091,0.04283836304787629,0.26190608952847944,0.22766472787959932,8644/1645,2
R-HSA-3656237,Defective EXT2 causes exostoses 2,2/265,14/11091,0.04283836304787629,0.26190608952847944,0.22766472787959932,6383/2719,2
R-HSA-3656253,"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",2/265,14/11091,0.04283836304787629,0.26190608952847944,0.22766472787959932,6383/2719,2
R-HSA-5578775,Ion homeostasis,4/265,56/11091,0.044441916023158244,0.2687240687550818,0.2335913307627461,6543/491/6547/478,4
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,6/265,108/11091,0.044668229513810144,0.2687240687550818,0.2335913307627461,2353/4128/3598/4318/3566/4988,6
R-HSA-5576892,Phase 0 - rapid depolarisation,3/265,34/11091,0.04683547969995172,0.27732504515247003,0.24106782340381291,775/6326/55800,3
R-HSA-9634815,Transcriptional Regulation by NPAS4,3/265,34/11091,0.04683547969995172,0.27732504515247003,0.24106782340381291,2353/30818/627,3
R-HSA-193807,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,2/265,15/11091,0.04866589451368033,0.2815134821099047,0.24470866795947763,8644/1645,2
R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,2/265,15/11091,0.04866589451368033,0.2815134821099047,0.24470866795947763,1482/25937,2
R-HSA-2162123,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),2/265,15/11091,0.04866589451368033,0.2815134821099047,0.24470866795947763,5730/8644,2
R-HSA-166658,Complement cascade,4/265,58/11091,0.04950283105051372,0.2841689232823383,0.2470169391913943,718/716/3426/715,4
R-HSA-1296065,Inwardly rectifying K+ channels,3/265,35/11091,0.050352513059349714,0.2868567410653863,0.24935335414558352,3761/3765/3768,3
R-HSA-2173791,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),2/265,16/11091,0.054761419368553714,0.3073178161578537,0.26713936706890695,50855/57530,2
R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,2/265,16/11091,0.054761419368553714,0.3073178161578537,0.26713936706890695,6850/7462,2
R-HSA-187037,Signaling by NTRK1 (TRKA),6/265,115/11091,0.0573968138023555,0.31884562591350374,0.2771600415625502,7425/2353/429/23237/6446/117,6
R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,4/265,61/11091,0.057663570643931523,0.31884562591350374,0.2771600415625502,1303/4318/3914/1297,4
R-HSA-913531,Interferon Signaling,11/265,269/11091,0.05824119256569324,0.3196888818204476,0.2778930509665425,7277/10382/57697/4137/2633/4938/3430/2635/7280/3106/4684,11
R-HSA-196757,Metabolism of folate and pterines,2/265,17/11091,0.061108910930294885,0.3306036044574227,0.2873807927884372,160428/6472,2
R-HSA-5602498,MyD88 deficiency (TLR2/4),2/265,17/11091,0.061108910930294885,0.3306036044574227,0.2873807927884372,7096/695,2
R-HSA-1442490,Collagen degradation,4/265,64/11091,0.06649924775383885,0.3559797106678163,0.30943925017457163,4327/1303/4318/1297,4
R-HSA-190242,FGFR1 ligand binding and activation,2/265,18/11091,0.06769295029986401,0.3559797106678163,0.30943925017457163,7049/2246,2
R-HSA-5603041,IRAK4 deficiency (TLR2/4),2/265,18/11091,0.06769295029986401,0.3559797106678163,0.30943925017457163,7096/695,2
R-HSA-9037629,Lewis blood group biosynthesis,2/265,18/11091,0.06769295029986401,0.3559797106678163,0.30943925017457163,8707/8708,2
R-HSA-2682334,EPH-Ephrin signaling,5/265,92/11091,0.06913184617395489,0.36102186335287556,0.31382219644755843,6383/1948/2902/4318/284656,5
R-HSA-170834,Signaling by TGF-beta Receptor Complex,5/265,94/11091,0.07433558265777193,0.3785339689087982,0.3290447854036446,7049/5054/50855/57530/25937,5
R-HSA-888590,"GABA synthesis, release, reuptake and degradation",2/265,19/11091,0.07449870664694433,0.3785339689087982,0.3290447854036446,6804/10815,2
R-HSA-9694614,Attachment and Entry,2/265,19/11091,0.07449870664694433,0.3785339689087982,0.3290447854036446,6383/2719,2
R-HSA-9840309,Glycosphingolipid biosynthesis,2/265,19/11091,0.07449870664694433,0.3785339689087982,0.3290447854036446,7368/2523,2
R-HSA-3928662,EPHB-mediated forward signaling,3/265,42/11091,0.07834942573709512,0.39279178769530354,0.34143855005428825,6383/1948/2902,3
R-HSA-8955332,Carboxyterminal post-translational modifications of tubulin,3/265,42/11091,0.07834942573709512,0.39279178769530354,0.34143855005428825,7277/10382/7280,3
R-HSA-877300,Interferon gamma signaling,5/265,96/11091,0.07974690812208456,0.3971501649523681,0.3452271170708575,2633/4938/2635/3106/4684,5
R-HSA-9646399,Aggrephagy,3/265,43/11091,0.08280460453593473,0.4043445624092397,0.3514809256104954,7277/10382/7280,3
R-HSA-977444,GABA B receptor activation,3/265,43/11091,0.08280460453593473,0.4043445624092397,0.3514809256104954,3761/3765/3768,3
R-HSA-991365,Activation of GABAB receptors,3/265,43/11091,0.08280460453593473,0.4043445624092397,0.3514809256104954,3761/3765/3768,3
R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,6/265,127/11091,0.08380284463866201,0.4065789623759602,0.3534232021773115,952/4907/160428/23057/6472/54981,6
R-HSA-451927,Interleukin-2 family signaling,3/265,44/11091,0.08736630208751504,0.4196012112294364,0.3647429341734043,3600/6850/3635,3
R-HSA-442982,Ras activation upon Ca2+ influx through NMDA receptor,2/265,21/11091,0.08871887311898988,0.4196012112294364,0.3647429341734043,2902/1741,2
R-HSA-445144,Signal transduction by L1,2/265,21/11091,0.08871887311898988,0.4196012112294364,0.3647429341734043,3897/4684,2
R-HSA-622312,Inflammasomes,2/265,21/11091,0.08871887311898988,0.4196012112294364,0.3647429341734043,834/22861,2
R-HSA-2172127,DAP12 interactions,3/265,45/11091,0.09203188239185733,0.43254984724172946,0.375998677403575,6850/3106/695,3
R-HSA-9609523,Insertion of tail-anchored proteins into the endoplasmic reticulum membrane,2/265,22/11091,0.09610639264971152,0.44338654768455865,0.3854185975813424,6804/9381,2
R-HSA-9617324,Negative regulation of NMDA receptor-mediated neuronal transmission,2/265,22/11091,0.09610639264971152,0.44338654768455865,0.3854185975813424,2902/1741,2
R-HSA-9768919,NPAS4 regulates expression of target genes,2/265,22/11091,0.09610639264971152,0.44338654768455865,0.3854185975813424,2353/627,2
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,6/265,134/11091,0.10185260576028639,0.46703146055936196,0.40597219625890796,5054/29106/7277/5582/226/7018,6
R-HSA-2187338,Visual phototransduction,5/265,104/11091,0.10341855831811965,0.46960050008375903,0.40820536191491374,4035/6383/8644/2719/1645,5
R-HSA-9820960,Respiratory syncytial virus (RSV) attachment and entry,2/265,23/11091,0.10366181251848935,0.46960050008375903,0.40820536191491374,6383/2719,2
R-HSA-375276,Peptide ligand-binding receptors,8/265,201/11091,0.10907623501250402,0.4813360394602512,0.41840660764951854,718/3627/6387/4852/2834/1910/7852/4988,8
R-HSA-428157,Sphingolipid metabolism,5/265,106/11091,0.10982726973407145,0.4813360394602512,0.41840660764951854,55512/7368/2523/130367/5587,5
R-HSA-8856825,Cargo recognition for clathrin-mediated endocytosis,5/265,106/11091,0.10982726973407145,0.4813360394602512,0.41840660764951854,6572/9892/7018/1129/85439,5
R-HSA-202733,Cell surface interactions at the vascular wall,6/265,137/11091,0.11016690551625334,0.4813360394602512,0.41840660764951854,6383/3897/972/7102/3635/57126,6
R-HSA-193368,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,2/265,24/11091,0.11137296657723898,0.4813360394602512,0.41840660764951854,8644/1645,2
R-HSA-2024096,HS-GAG degradation,2/265,24/11091,0.11137296657723898,0.4813360394602512,0.41840660764951854,6383/2719,2
R-HSA-210500,Glutamate Neurotransmitter Release Cycle,2/265,24/11091,0.11137296657723898,0.4813360394602512,0.41840660764951854,6804/10815,2
R-HSA-9620244,Long-term potentiation,2/265,24/11091,0.11137296657723898,0.4813360394602512,0.41840660764951854,2902/1741,2
R-HSA-163685,Integration of energy metabolism,5/265,108/11091,0.11642473259708082,0.49915036002577695,0.4338919003023622,6804/775/1131/6861/3745,5
R-HSA-1483249,Inositol phosphate metabolism,3/265,50/11091,0.11682242468688397,0.49915036002577695,0.4338919003023622,55190/3635/170685,3
R-HSA-2029485,Role of phospholipids in phagocytosis,2/265,25/11091,0.11922817026865816,0.5049192566988314,0.4389065767216886,5337/6850,2
R-HSA-2672351,Stimuli-sensing channels,5/265,109/11091,0.11979289678159814,0.5049192566988314,0.4389065767216886,57578/80036/6446/285175/59341,5
R-HSA-6806834,Signaling by MET,4/265,79/11091,0.12018689753868461,0.5049192566988314,0.4389065767216886,3910/3673/10319/3914,4
R-HSA-3928665,EPH-ephrin mediated repulsion of cells,3/265,51/11091,0.1220534320343129,0.5099121160544628,0.4432466742298733,1948/4318/284656,3
R-HSA-70263,Gluconeogenesis,2/265,26/11091,0.12721620470205794,0.5285446736792684,0.45944322838021506,226/2026,2
R-HSA-3000170,Syndecan interactions,2/265,27/11091,0.1353263012106497,0.55307270929569885,0.4807644911430977,3673/6383,2
R-HSA-354192,Integrin signaling,2/265,27/11091,0.1353263012106497,0.55307270929569885,0.4807644911430977,6850/10235,2
R-HSA-9733709,Cardiogenesis,2/265,27/11091,0.1353263012106497,0.55307270929569885,0.4807644911430977,51176/1482,2
R-HSA-418594,G alpha (i) signalling events,11/265,318/11091,0.14059252794961372,0.5714896271249164,0.4967735980467148,5582/718/3627/6387/4852/23566/3352/2912/7852/4988/1129,11
R-HSA-3295583,TRP channels,2/265,28/11091,0.14354812637650669,0.5721229948634474,0.49732415986870226,80036/59341,2
R-HSA-5621480,Dectin-2 family,2/265,28/11091,0.14354812637650669,0.5721229948634474,0.49732415986870226,6850/4585,2
R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,3/265,55/11091,0.14379155057073348,0.5721229948634474,0.49732415986870226,7277/10382/7280,3
R-HSA-9824272,Somitogenesis,3/265,55/11091,0.14379155057073348,0.5721229948634474,0.49732415986870226,51176/3955/84667,3
R-HSA-216083,Integrin cell surface interactions,4/265,85/11091,0.1456286671250713,0.5763829351476506,0.501027159471852,3673/22801/1297/3679,4
R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,6/265,149/11091,0.14670705751447927,0.5776110327271645,0.5020946967015245,7277/10382/57697/4137/4938/7280,6
R-HSA-442742,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,2/265,29/11091,0.15187176750979775,0.5948310894133745,0.5170634189889496,2902/1741,2
R-HSA-948021,Transport to the Golgi and subsequent modification,7/265,185/11091,0.15478293574191654,0.603092060507364,0.5242443583077729,7277/57731/10382/286/51046/7280/63908,7
R-HSA-983712,Ion channel transport,7/265,186/11091,0.15779066417964271,0.6103321163399851,0.5305378558890408,57578/80036/491/6446/285175/59341/478,7
R-HSA-2980736,Peptide hormone metabolism,4/265,88/11091,0.15907592393967696,0.6103321163399851,0.5305378558890408,6804/43/3800/3798,4
R-HSA-418346,Platelet homeostasis,4/265,88/11091,0.15907592393967696,0.6103321163399851,0.5305378558890408,6543/5138/491/6547,4
R-HSA-2424491,DAP12 signaling,2/265,30/11091,0.160287718569261,0.6109764707114058,0.5310979679616225,6850/695,2
R-HSA-1660662,Glycosphingolipid metabolism,3/265,58/11091,0.16086880478837545,0.6109764707114058,0.5310979679616225,55512/7368/2523,3
R-HSA-199977,ER to Golgi Anterograde Transport,6/265,154/11091,0.16337787239209411,0.6173877388887175,0.536671032824599,7277/57731/10382/286/7280/63908,6
R-HSA-380108,Chemokine receptors bind chemokines,3/265,59/11091,0.16669316403108805,0.626766296756891,0.5448234466489773,3627/6387/7852,3
R-HSA-1474290,Collagen formation,4/265,90/11091,0.1682862544259347,0.6296082752651885,0.5472938674967555,1303/4318/3914/1297,4
R-HSA-2132295,MHC class II antigen presentation,5/265,123/11091,0.1714382880286136,0.6381582751069881,0.5547260482103018,7277/10382/972/3798/7280,5
R-HSA-977443,GABA receptor activation,3/265,60/11091,0.17257871005604405,0.6381582751069881,0.5547260482103018,3761/3765/3768,3
R-HSA-9006936,Signaling by TGFB family members,5/265,124/11091,0.17542061382100527,0.6381582751069881,0.5547260482103018,7049/5054/50855/57530/25937,5
R-HSA-1251985,Nuclear signaling by ERBB4,2/265,32/11091,0.17736047805500066,0.6381582751069881,0.5547260482103018,6285/6387,2
R-HSA-2871796,FCERI mediated MAPK activation,2/265,32/11091,0.17736047805500066,0.6381582751069881,0.5547260482103018,2353/6850,2
R-HSA-451326,Activation of kainate receptors upon glutamate binding,2/265,32/11091,0.17736047805500066,0.6381582751069881,0.5547260482103018,2901/1741,2
R-HSA-5260271,Diseases of Immune System,2/265,32/11091,0.17736047805500066,0.6381582751069881,0.5547260482103018,7096/695,2
R-HSA-5602358,Diseases associated with the TLR signaling cascade,2/265,32/11091,0.17736047805500066,0.6381582751069881,0.5547260482103018,7096/695,2
R-HSA-8986944,Transcriptional Regulation by MECP2,3/265,62/11091,0.18452199724695714,0.6597742477022365,0.5735159683973808,627/6446/4988,3
R-HSA-2871809,FCERI mediated Ca+2 mobilization,2/265,33/11091,0.18600018685222625,0.6597742477022365,0.5735159683973808,6850/695,2
R-HSA-420092,Glucagon-type ligand receptors,2/265,33/11091,0.18600018685222625,0.6597742477022365,0.5735159683973808,7432/117,2
R-HSA-192105,Synthesis of bile acids and bile salts,2/265,34/11091,0.19469798104924343,0.6873844213569533,0.5975164133016071,8644/1645,2
R-HSA-114608,Platelet degranulation,5/265,129/11091,0.19584435266376468,0.6879091404824939,0.5979725311304992,5054/29106/7277/226/7018,5
R-HSA-913709,O-linked glycosylation of mucins,3/265,64/11091,0.1966761505368832,0.6879091404824939,0.5979725311304992,79623/4585/442117,3
R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,7/265,202/11091,0.209320861499327,0.7182131047494138,0.6243145829358707,7277/10382/3798/51560/7280/547/63908,7
R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,2/265,36/11091,0.21223747873204893,0.7182131047494138,0.6243145829358707,5054/25937,2
R-HSA-168799,Neurotoxicity of clostridium toxins,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,6804,1
R-HSA-190377,FGFR2b ligand binding and activation,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,2246,1
R-HSA-193697,p75NTR regulates axonogenesis,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,84894,1
R-HSA-209968,Thyroxine biosynthesis,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,1735,1
R-HSA-399997,Acetylcholine regulates insulin secretion,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,1131,1
R-HSA-418889,Caspase activation via Dependence Receptors in the absence of ligand,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,90249,1
R-HSA-450341,Activation of the AP-1 family of transcription factors,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,2353,1
R-HSA-9757110,Prednisone ADME,1/265,10/11091,0.21489088905401343,0.7182131047494138,0.6243145829358707,1645,1
R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,5/265,134/11091,0.21704837688146247,0.7222140682073441,0.6277924641052083,2353/6850/10235/7462/695,5
R-HSA-9793380,Formation of paraxial mesoderm,3/265,69/11091,0.2278400773142196,0.7343690249102176,0.6383582929300744,51176/3955/84667,3
R-HSA-9772572,Early SARS-CoV-2 Infection Events,2/265,38/11091,0.22992151718925563,0.7343690249102176,0.6383582929300744,6383/2719,2
R-HSA-1236977,Endosomal/Vacuolar pathway,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,3106,1
R-HSA-1839122,Signaling by activated point mutants of FGFR1,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,2246,1
R-HSA-196025,Formation of annular gap junctions,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,2697,1
R-HSA-446107,Type I hemidesmosome assembly,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,3914,1
R-HSA-5625970,RHO GTPases activate KTN1,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,3798,1
R-HSA-71288,Creatine metabolism,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,2628,1
R-HSA-9028731,Activated NTRK2 signals through FRS2 and FRS3,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,627,1
R-HSA-9690406,Transcriptional regulation of testis differentiation,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,5730,1
R-HSA-9701898,STAT3 nuclear events downstream of ALK signaling,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,29126,1
R-HSA-9845614,Sphingolipid catabolism,1/265,11/11091,0.2336666235906697,0.7343690249102176,0.6383582929300744,130367,1
R-HSA-76009,Platelet Aggregation (Plug Formation),2/265,39/11091,0.23880114437169103,0.7343690249102176,0.6383582929300744,6850/10235,2
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,2/265,39/11091,0.23880114437169103,0.7343690249102176,0.6383582929300744,4254/51176,2
R-HSA-449147,Signaling by Interleukins,14/265,473/11091,0.24161710794268923,0.7343690249102176,0.6383582929300744,6804/3589/3600/2353/6285/4128/3627/3598/4318/3566/6850/834/3635/4988,14
R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,3/265,72/11091,0.24696636972246436,0.7343690249102176,0.6383582929300744,7277/10382/7280,3
R-HSA-1839130,Signaling by activated point mutants of FGFR3,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,2246,1
R-HSA-190873,Gap junction degradation,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,2697,1
R-HSA-2029481,FCGR activation,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,6850,1
R-HSA-2033514,FGFR3 mutant receptor activation,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,2246,1
R-HSA-210990,PECAM1 interactions,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,3635,1
R-HSA-264870,Caspase-mediated cleavage of cytoskeletal proteins,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,4137,1
R-HSA-4641265,Repression of WNT target genes,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,51176,1
R-HSA-622323,Presynaptic nicotinic acetylcholine receptors,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,1141,1
R-HSA-629594,Highly calcium permeable postsynaptic nicotinic acetylcholine receptors,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,1141,1
R-HSA-6803207,TP53 Regulates Transcription of Caspase Activators and Caspases,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,834,1
R-HSA-71064,Lysine catabolism,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,51268,1
R-HSA-73621,Pyrimidine catabolism,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,4907,1
R-HSA-9020558,Interleukin-2 signaling,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,6850,1
R-HSA-9827857,Specification of primordial germ cells,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,7852,1
R-HSA-9831926,Nephron development,1/265,12/11091,0.2519949940553332,0.7343690249102176,0.6383582929300744,3955,1
R-HSA-416476,G alpha (q) signalling events,7/265,216/11091,0.25886421131983245,0.7343690249102176,0.6383582929300744,1131/1128/3357/23566/10235/1910/695,7
R-HSA-1980143,Signaling by NOTCH1,3/265,74/11091,0.2598532040255168,0.7343690249102176,0.6383582929300744,92737/8788/3714,3
R-HSA-2995410,Nuclear Envelope (NE) Reassembly,3/265,75/11091,0.26633011693483194,0.7343690249102176,0.6383582929300744,7277/10382/7280,3
R-HSA-1237044,Erythrocytes take up carbon dioxide and release oxygen,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,358,1
R-HSA-1480926,O2/CO2 exchange in erythrocytes,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,358,1
R-HSA-1483213,Synthesis of PE,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,64900,1
R-HSA-190239,FGFR3 ligand binding and activation,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,2246,1
R-HSA-190372,FGFR3c ligand binding and activation,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,2246,1
R-HSA-190375,FGFR2c ligand binding and activation,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,2246,1
R-HSA-2168880,Scavenging of heme from plasma,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,4035,1
R-HSA-2892247,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,57167,1
R-HSA-3270619,IRF3-mediated induction of type I IFN,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,3428,1
R-HSA-419408,Lysosphingolipid and LPA receptors,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,23566,1
R-HSA-5654227,Phospholipase C-mediated cascade; FGFR3,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,2246,1
R-HSA-74217,Purine salvage,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,2766,1
R-HSA-75109,Triglyceride biosynthesis,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,64900,1
R-HSA-75205,Dissolution of Fibrin Clot,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,5054,1
R-HSA-879415,Advanced glycosylation endproduct receptor signaling,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,6285,1
R-HSA-9768759,Regulation of NPAS4 gene expression,1/265,13/11091,0.2698866202468069,0.7343690249102176,0.6383582929300744,30818,1
R-HSA-8856828,Clathrin-mediated endocytosis,5/265,146/11091,0.2705056115693222,0.7343690249102176,0.6383582929300744,6572/9892/7018/1129/85439,5
R-HSA-1433557,Signaling by SCF-KIT,2/265,43/11091,0.2744305914175271,0.7396838879784244,0.6429782956811332,4254/4318,2
R-HSA-5362517,Signaling by Retinoic Acid,2/265,43/11091,0.2744305914175271,0.7396838879784244,0.6429782956811332,8644/1382,2
R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,3/265,77/11091,0.27933919246737726,0.742572532103193,0.6454892811255359,7277/10382/7280,3
R-HSA-909733,Interferon alpha/beta signaling,3/265,77/11091,0.27933919246737726,0.742572532103193,0.6454892811255359,4938/3430/3106,3
R-HSA-8948216,Collagen chain trimerization,2/265,44/11091,0.2833384147189566,0.742572532103193,0.6454892811255359,1303/1297,2
R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,4/265,113/11091,0.2847046929021457,0.742572532103193,0.6454892811255359,2353/6285/7096/695,4
R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,4/265,113/11091,0.2847046929021457,0.742572532103193,0.6454892811255359,2353/6285/7096/695,4
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,3/265,78/11091,0.28586678786890235,0.742572532103193,0.6454892811255359,4254/118788/2246,3
R-HSA-162594,Early Phase of HIV Life Cycle,1/265,14/11091,0.2873518708005707,0.742572532103193,0.6454892811255359,7852,1
R-HSA-190322,FGFR4 ligand binding and activation,1/265,14/11091,0.2873518708005707,0.742572532103193,0.6454892811255359,2246,1
R-HSA-5660526,Response to metal ions,1/265,14/11091,0.2873518708005707,0.742572532103193,0.6454892811255359,6620,1
R-HSA-8983432,Interleukin-15 signaling,1/265,14/11091,0.2873518708005707,0.742572532103193,0.6454892811255359,3600,1
R-HSA-9796292,Formation of axial mesoderm,1/265,14/11091,0.2873518708005707,0.742572532103193,0.6454892811255359,51176,1
R-HSA-9825892,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,1/265,14/11091,0.2873518708005707,0.742572532103193,0.6454892811255359,51176,1
R-HSA-194068,Bile acid and bile salt metabolism,2/265,45/11091,0.2922363929667283,0.7456333992452652,0.6481499733081042,8644/1645,2
R-HSA-76002,"Platelet activation, signaling and aggregation",8/265,263/11091,0.29339213619890825,0.7456333992452652,0.6481499733081042,5054/29106/7277/5582/6850/10235/226/7018,8
R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,4/265,116/11091,0.3008253843014896,0.7456333992452652,0.6481499733081042,2353/6285/7096/695,4
R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,4/265,116/11091,0.3008253843014896,0.7456333992452652,0.6481499733081042,2353/6285/7096/695,4
R-HSA-9830369,Kidney development,2/265,46/11091,0.3011199264446175,0.7456333992452652,0.6481499733081042,3955/2674,2
R-HSA-181431,Acetylcholine binding and downstream events,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,1141,1
R-HSA-2214320,Anchoring fibril formation,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,3914,1
R-HSA-2691230,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,3714,1
R-HSA-2691232,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,3714,1
R-HSA-4419969,Depolymerization of the Nuclear Lamina,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,64900,1
R-HSA-5099900,WNT5A-dependent internalization of FZD4,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,5582,1
R-HSA-5576893,Phase 2 - plateau phase,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,775,1
R-HSA-5654228,Phospholipase C-mediated cascade; FGFR4,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,2246,1
R-HSA-622327,Postsynaptic nicotinic acetylcholine receptors,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,1141,1
R-HSA-975577,N-Glycan antennae elongation,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,51046,1
R-HSA-9823730,Formation of definitive endoderm,1/265,15/11091,0.3044008691067771,0.7456333992452652,0.6481499733081042,7852,1
R-HSA-9663891,Selective autophagy,3/265,81/11091,0.30551532914510166,0.7459335308997287,0.6484108660256601,7277/10382/7280,3
R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",2/265,48/11091,0.31882637113434475,0.7615921492592196,0.6620222909994057,6850/3635,2
R-HSA-1433559,Regulation of KIT signaling,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,4254,1
R-HSA-1834941,STING mediated induction of host immune responses,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,3428,1
R-HSA-392517,Rap1 signalling,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,10235,1
R-HSA-399956,CRMPs in Sema3A signaling,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,56896,1
R-HSA-418457,cGMP effects,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,5138,1
R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,2246,1
R-HSA-75892,Platelet Adhesion to exposed collagen,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,3673,1
R-HSA-844456,The NLRP3 inflammasome,1/265,16/11091,0.3210434990893253,0.7615921492592196,0.6620222909994057,834,1
R-HSA-6811440,Retrograde transport at the Trans-Golgi-Network,2/265,49/11091,0.32764117007868754,0.7713024513382317,0.6704630771011225,51560/63908,2
R-HSA-9012852,Signaling by NOTCH3,2/265,49/11091,0.32764117007868754,0.7713024513382317,0.6704630771011225,10320/3714,2
R-HSA-1502540,Signaling by Activin,1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,7049,1
R-HSA-2033519,Activated point mutants of FGFR2,1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,2246,1
R-HSA-2142845,Hyaluronan metabolism,1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,3037,1
R-HSA-6788467,IL-6-type cytokine receptor ligand interactions,1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,3589,1
R-HSA-9022699,MECP2 regulates neuronal receptors and channels,1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,4988,1
R-HSA-9659787,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,1028,1
R-HSA-9661069,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,1028,1
R-HSA-9754189,Germ layer formation at gastrulation,1/265,17/11091,0.3372894108492649,0.7713024513382317,0.6704630771011225,51176,1
R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,3/265,86/11091,0.3383571460034175,0.7713024513382317,0.6704630771011225,5337/6850/695,3
R-HSA-2559580,Oxidative Stress Induced Senescence,4/265,124/11091,0.34423308253534046,0.7713024513382317,0.6704630771011225,2353/4217/8338/23043,4
R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,2/265,51/11091,0.3451751559980003,0.7713024513382317,0.6704630771011225,5054/25937,2
R-HSA-9758941,Gastrulation,4/265,125/11091,0.3496808496987562,0.7713024513382317,0.6704630771011225,51176/3955/7852/84667,4
R-HSA-1912420,Pre-NOTCH Processing in Golgi,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,3955,1
R-HSA-209776,Metabolism of amine-derived hormones,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,1735,1
R-HSA-446353,Cell-extracellular matrix interactions,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,2318,1
R-HSA-5083625,Defective GALNT3 causes HFTC,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,4585,1
R-HSA-5083636,Defective GALNT12 causes CRCS1,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,4585,1
R-HSA-5654221,Phospholipase C-mediated cascade; FGFR2,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,2246,1
R-HSA-5654704,SHC-mediated cascade:FGFR3,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,2246,1
R-HSA-5654710,PI-3K cascade:FGFR3,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,2246,1
R-HSA-74259,Purine catabolism,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,4907,1
R-HSA-8964315,G beta:gamma signalling through BTK,1/265,18/11091,0.3531480261757003,0.7713024513382317,0.6704630771011225,695,1
R-HSA-383280,Nuclear Receptor transcription pathway,2/265,52/11091,0.3538874125891477,0.7713024513382317,0.6704630771011225,2104/8013,2
R-HSA-445717,Aquaporin-mediated transport,2/265,52/11091,0.3538874125891477,0.7713024513382317,0.6704630771011225,358/89872,2
R-HSA-5654736,Signaling by FGFR1,2/265,52/11091,0.3538874125891477,0.7713024513382317,0.6704630771011225,7049/2246,2
R-HSA-9658195,Leishmania infection,5/265,164/11091,0.35488118106785665,0.7713024513382317,0.6704630771011225,4907/718/6850/834/695,5
R-HSA-9824443,Parasitic Infection Pathways,5/265,164/11091,0.35488118106785665,0.7713024513382317,0.6704630771011225,4907/718/6850/834/695,5
R-HSA-1236974,ER-Phagosome pathway,3/265,90/11091,0.36457619504584815,0.7852936686496538,0.6826250955087277,7096/3106/695,3
R-HSA-390466,Chaperonin-mediated protein folding,3/265,90/11091,0.36457619504584815,0.7852936686496538,0.6826250955087277,7277/10382/7280,3
R-HSA-3928664,Ephrin signaling,1/265,19/11091,0.3686285439272976,0.7852936686496538,0.6826250955087277,1948,1
R-HSA-422085,"Synthesis, secretion, and deacylation of Ghrelin",1/265,19/11091,0.3686285439272976,0.7852936686496538,0.6826250955087277,43,1
R-HSA-442660,Na+/Cl- dependent neurotransmitter transporters,1/265,19/11091,0.3686285439272976,0.7852936686496538,0.6826250955087277,6570,1
R-HSA-5083632,Defective C1GALT1C1 causes TNPS,1/265,19/11091,0.3686285439272976,0.7852936686496538,0.6826250955087277,4585,1
R-HSA-8851708,Signaling by FGFR2 IIIa TM,1/265,19/11091,0.3686285439272976,0.7852936686496538,0.6826250955087277,2246,1
R-HSA-9662361,Sensory processing of sound by outer hair cells of the cochlea,2/265,54/11091,0.3711864832082118,0.7868935769416939,0.6840158332597872,491/494513,2
R-HSA-1483206,Glycerophospholipid biosynthesis,4/265,129/11091,0.3714723667743369,0.7868935769416939,0.6840158332597872,43/5337/1103/64900,4
R-HSA-983231,Factors involved in megakaryocyte development and platelet production,5/265,168/11091,0.3739163760877321,0.7898458281403778,0.686582109847669,7277/10382/3798/7280/547,5
R-HSA-190241,FGFR2 ligand binding and activation,1/265,20/11091,0.3837399452874193,0.7993696367206076,0.6948607844393859,2246,1
R-HSA-2028269,Signaling by Hippo,1/265,20/11091,0.3837399452874193,0.7993696367206076,0.6948607844393859,25937,1
R-HSA-5654706,FRS-mediated FGFR3 signaling,1/265,20/11091,0.3837399452874193,0.7993696367206076,0.6948607844393859,2246,1
R-HSA-5654719,SHC-mediated cascade:FGFR4,1/265,20/11091,0.3837399452874193,0.7993696367206076,0.6948607844393859,2246,1
R-HSA-5654720,PI-3K cascade:FGFR4,1/265,20/11091,0.3837399452874193,0.7993696367206076,0.6948607844393859,2246,1
R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,3/265,94/11091,0.3906255049908227,0.8099133961837842,0.7040260624721866,7277/10382/7280,3
R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",2/265,57/11091,0.3967786454460085,0.8099133961837842,0.7040260624721866,834/22861,2
R-HSA-75893,TNF signaling,2/265,57/11091,0.3967786454460085,0.8099133961837842,0.7040260624721866,55512/7185,2
R-HSA-936837,Ion transport by P-type ATPases,2/265,57/11091,0.3967786454460085,0.8099133961837842,0.7040260624721866,491/478,2
R-HSA-5654688,SHC-mediated cascade:FGFR1,1/265,21/11091,0.3984909988958406,0.8099133961837842,0.7040260624721866,2246,1
R-HSA-5654689,PI-3K cascade:FGFR1,1/265,21/11091,0.3984909988958406,0.8099133961837842,0.7040260624721866,2246,1
R-HSA-9008059,Interleukin-37 signaling,1/265,21/11091,0.3984909988958406,0.8099133961837842,0.7040260624721866,834,1
R-HSA-9830674,Formation of the ureteric bud,1/265,21/11091,0.3984909988958406,0.8099133961837842,0.7040260624721866,2674,1
R-HSA-391251,Protein folding,3/265,96/11091,0.4035548896973473,0.8099133961837842,0.7040260624721866,7277/10382/7280,3
R-HSA-9609690,HCMV Early Events,4/265,135/11091,0.40404790946264324,0.8099133961837842,0.7040260624721866,7277/10382/8338/7280,4
R-HSA-1236394,Signaling by ERBB4,2/265,58/11091,0.4052039968980663,0.8099133961837842,0.7040260624721866,6285/6387,2
R-HSA-140875,Common Pathway of Fibrin Clot Formation,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,57126,1
R-HSA-2979096,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,3714,1
R-HSA-392154,Nitric oxide stimulates guanylate cyclase,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,5138,1
R-HSA-5365859,RA biosynthesis pathway,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,8644,1
R-HSA-5654712,FRS-mediated FGFR4 signaling,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,2246,1
R-HSA-5655332,Signaling by FGFR3 in disease,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,2246,1
R-HSA-5686938,Regulation of TLR by endogenous ligand,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,7096,1
R-HSA-912631,Regulation of signaling by CBL,1/265,22/11091,0.41289026585994226,0.8099133961837842,0.7040260624721866,6850,1
R-HSA-2142753,Arachidonic acid metabolism,2/265,59/11091,0.4135727980512941,0.8099133961837842,0.7040260624721866,5730/8644,2
R-HSA-9664407,Parasite infection,2/265,59/11091,0.4135727980512941,0.8099133961837842,0.7040260624721866,6850/695,2
R-HSA-9664417,Leishmania phagocytosis,2/265,59/11091,0.4135727980512941,0.8099133961837842,0.7040260624721866,6850/695,2
R-HSA-9664422,FCGR3A-mediated phagocytosis,2/265,59/11091,0.4135727980512941,0.8099133961837842,0.7040260624721866,6850/695,2
R-HSA-9833110,RSV-host interactions,3/265,98/11091,0.4164053170336478,0.8133423335306575,0.7070067036989619,6383/4131/2719,3
R-HSA-9679191,Potential therapeutics for SARS,3/265,99/11091,0.42279754607996156,0.8190394660597927,0.7119589983526474,6850/478/695,3
R-HSA-389948,PD-1 signaling,1/265,23/11091,0.42694610464818983,0.8190394660597927,0.7119589983526474,29126,1
R-HSA-5654693,FRS-mediated FGFR1 signaling,1/265,23/11091,0.42694610464818983,0.8190394660597927,0.7119589983526474,2246,1
R-HSA-5654695,PI-3K cascade:FGFR2,1/265,23/11091,0.42694610464818983,0.8190394660597927,0.7119589983526474,2246,1
R-HSA-5654699,SHC-mediated cascade:FGFR2,1/265,23/11091,0.42694610464818983,0.8190394660597927,0.7119589983526474,2246,1
R-HSA-8949215,Mitochondrial calcium ion transport,1/265,23/11091,0.42694610464818983,0.8190394660597927,0.7119589983526474,6547,1
R-HSA-8956321,Nucleotide salvage,1/265,23/11091,0.42694610464818983,0.8190394660597927,0.7119589983526474,2766,1
R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,2/265,61/11091,0.43013244215018265,0.8230524083891536,0.7154472922867644,6850/695,2
R-HSA-202040,G-protein activation,1/265,24/11091,0.44066667586866615,0.8305296748201426,0.7219469877705889,4988,1
R-HSA-449836,Other interleukin signaling,1/265,24/11091,0.44066667586866615,0.8305296748201426,0.7219469877705889,6804,1
R-HSA-452723,Transcriptional regulation of pluripotent stem cells,1/265,24/11091,0.44066667586866615,0.8305296748201426,0.7219469877705889,57167,1
R-HSA-6783589,Interleukin-6 family signaling,1/265,24/11091,0.44066667586866615,0.8305296748201426,0.7219469877705889,3589,1
R-HSA-8940973,RUNX2 regulates osteoblast differentiation,1/265,24/11091,0.44066667586866615,0.8305296748201426,0.7219469877705889,25937,1
R-HSA-9634638,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,1/265,24/11091,0.44066667586866615,0.8305296748201426,0.7219469877705889,2353,1
R-HSA-9033241,Peroxisomal protein import,2/265,63/11091,0.4464422553003349,0.8333976696889552,0.724440023623798,283927/51268,2
R-HSA-210991,Basigin interactions,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,3897,1
R-HSA-5654700,FRS-mediated FGFR2 signaling,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,2246,1
R-HSA-5654708,Downstream signaling of activated FGFR3,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,2246,1
R-HSA-9006115,Signaling by NTRK2 (TRKB),1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,627,1
R-HSA-9013507,NOTCH3 Activation and Transmission of Signal to the Nucleus,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,3714,1
R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,10320,1
R-HSA-933542,TRAF6 mediated NF-kB activation,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,6285,1
R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,6850,1
R-HSA-977068,Termination of O-glycan biosynthesis,1/265,25/11091,0.4540599469353329,0.8333976696889552,0.724440023623798,4585,1
R-HSA-2219528,PI3K/AKT Signaling in Cancer,3/265,104/11091,0.4543790486336059,0.8333976696889552,0.724440023623798,4254/118788/2246,3
R-HSA-1236975,Antigen processing-Cross presentation,3/265,105/11091,0.4606113524983553,0.8427730829166987,0.7325897039351483,7096/3106/695,3
R-HSA-8873719,RAB geranylgeranylation,2/265,65/11091,0.46248887258267346,0.844154447044103,0.7337904697849775,5865/51560,2
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",3/265,106/11091,0.46681315461347905,0.8461150621810836,0.7354947558992904,4254/118788/2246,3
R-HSA-5223345,Miscellaneous transport and binding events,1/265,26/11091,0.4671336966246642,0.8461150621810836,0.7354947558992904,2039,1
R-HSA-975576,N-glycan antennae elongation in the medial/trans-Golgi,1/265,26/11091,0.4671336966246642,0.8461150621810836,0.7354947558992904,51046,1
R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,4/265,147/11091,0.4680636514193228,0.8461150621810836,0.7354947558992904,2353/6285/7096/695,4
R-HSA-1650814,Collagen biosynthesis and modifying enzymes,2/265,67/11091,0.47826073711391515,0.8551692670212147,0.7433652223126742,1303/1297,2
R-HSA-9018519,Estrogen-dependent gene expression,4/265,149/11091,0.4785095313798172,0.8551692670212147,0.7433652223126742,2353/6387/8338/8204,4
R-HSA-114508,Effects of PIP2 hydrolysis,1/265,27/11091,0.47989551952520293,0.8551692670212147,0.7433652223126742,10235,1
R-HSA-5357769,Caspase activation via extrinsic apoptotic signalling pathway,1/265,27/11091,0.47989551952520293,0.8551692670212147,0.7433652223126742,90249,1
R-HSA-5654716,Downstream signaling of activated FGFR4,1/265,27/11091,0.47989551952520293,0.8551692670212147,0.7433652223126742,2246,1
R-HSA-912526,Interleukin receptor SHC signaling,1/265,27/11091,0.47989551952520293,0.8551692670212147,0.7433652223126742,3635,1
R-HSA-1855204,Synthesis of IP3 and IP4 in the cytosol,1/265,28/11091,0.49235283038256217,0.8637563131151323,0.7508296058853544,3635,1
R-HSA-400042,"Adrenaline,noradrenaline inhibits insulin secretion",1/265,28/11091,0.49235283038256217,0.8637563131151323,0.7508296058853544,775,1
R-HSA-5620971,Pyroptosis,1/265,28/11091,0.49235283038256217,0.8637563131151323,0.7508296058853544,834,1
R-HSA-157118,Signaling by NOTCH,6/265,235/11091,0.49301281428106825,0.8637563131151323,0.7508296058853544,3955/10320/92737/8788/3714/8338,6
R-HSA-3371453,Regulation of HSF1-mediated heat shock response,2/265,69/11091,0.49374796022570555,0.8637563131151323,0.7508296058853544,9531/259217,2
R-HSA-380259,Loss of Nlp from mitotic centrosomes,2/265,70/11091,0.5013821648438619,0.8637563131151323,0.7508296058853544,7277/10382,2
R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,2/265,70/11091,0.5013821648438619,0.8637563131151323,0.7508296058853544,7277/10382,2
R-HSA-983705,Signaling by the B Cell Receptor (BCR),3/265,112/11091,0.5033303449299988,0.8637563131151323,0.7508296058853544,118788/6850/695,3
R-HSA-390918,Peroxisomal lipid metabolism,1/265,29/11091,0.5045128683423037,0.8637563131151323,0.7508296058853544,283927,1
R-HSA-420029,Tight junction interactions,1/265,29/11091,0.5045128683423037,0.8637563131151323,0.7508296058853544,50855,1
R-HSA-5654732,Negative regulation of FGFR3 signaling,1/265,29/11091,0.5045128683423037,0.8637563131151323,0.7508296058853544,2246,1
R-HSA-9615017,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",1/265,29/11091,0.5045128683423037,0.8637563131151323,0.7508296058853544,4852,1
R-HSA-983170,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",1/265,29/11091,0.5045128683423037,0.8637563131151323,0.7508296058853544,3106,1
R-HSA-5673001,RAF/MAP kinase cascade,7/265,280/11091,0.5058000550450988,0.8637563131151323,0.7508296058853544,4254/57731/2902/2674/1741/4684/2246,7
R-HSA-199418,Negative regulation of the PI3K/AKT network,3/265,113/11091,0.509292862712577,0.8637563131151323,0.7508296058853544,4254/118788/2246,3
R-HSA-5610787,Hedgehog 'off' state,3/265,113/11091,0.509292862712577,0.8637563131151323,0.7508296058853544,7277/10382/7280,3
R-HSA-9730414,MITF-M-regulated melanocyte development,3/265,114/11091,0.5152179483326832,0.8637563131151323,0.7508296058853544,4254/51176/2766,3
R-HSA-201556,Signaling by ALK,1/265,30/11091,0.5163827010930984,0.8637563131151323,0.7508296058853544,29126,1
R-HSA-2173795,Downregulation of SMAD2/3:SMAD4 transcriptional activity,1/265,30/11091,0.5163827010930984,0.8637563131151323,0.7508296058853544,25937,1
R-HSA-3928663,EPHA-mediated growth cone collapse,1/265,30/11091,0.5163827010930984,0.8637563131151323,0.7508296058853544,284656,1
R-HSA-5654696,Downstream signaling of activated FGFR2,1/265,30/11091,0.5163827010930984,0.8637563131151323,0.7508296058853544,2246,1
R-HSA-9674555,Signaling by CSF3 (G-CSF),1/265,30/11091,0.5163827010930984,0.8637563131151323,0.7508296058853544,6850,1
R-HSA-9843743,Transcriptional regulation of brown and beige adipocyte differentiation,1/265,30/11091,0.5163827010930984,0.8637563131151323,0.7508296058853544,655,1
R-HSA-9844594,Transcriptional regulation of brown and beige adipocyte differentiation by EBF2,1/265,30/11091,0.5163827010930984,0.8637563131151323,0.7508296058853544,655,1
R-HSA-446728,Cell junction organization,3/265,115/11091,0.5211048932238,0.8637563131151323,0.7508296058853544,50855/2318/3914,3
R-HSA-606279,Deposition of new CENPA-containing nucleosomes at the centromere,2/265,73/11091,0.5238364927717187,0.8637563131151323,0.7508296058853544,55320/8338,2
R-HSA-70171,Glycolysis,2/265,73/11091,0.5238364927717187,0.8637563131151323,0.7508296058853544,226/2026,2
R-HSA-774815,Nucleosome assembly,2/265,73/11091,0.5238364927717187,0.8637563131151323,0.7508296058853544,55320/8338,2
R-HSA-8854518,AURKA Activation by TPX2,2/265,73/11091,0.5238364927717187,0.8637563131151323,0.7508296058853544,7277/10382,2
R-HSA-1839124,FGFR1 mutant receptor activation,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,2246,1
R-HSA-201451,Signaling by BMP,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,7049,1
R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,2353,1
R-HSA-5339562,Uptake and actions of bacterial toxins,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,6804,1
R-HSA-5654687,Downstream signaling of activated FGFR1,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,2246,1
R-HSA-5654733,Negative regulation of FGFR4 signaling,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,2246,1
R-HSA-917977,Transferrin endocytosis and recycling,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,7018,1
R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,1/265,31/11091,0.5279692289124931,0.8637563131151323,0.7508296058853544,3635,1
R-HSA-5684996,MAPK1/MAPK3 signaling,7/265,286/11091,0.528361574511916,0.8637563131151323,0.7508296058853544,4254/57731/2902/2674/1741/4684/2246,7
R-HSA-9013408,RHOG GTPase cycle,2/265,74/11091,0.5311693619035578,0.8664628202851962,0.7531822667932627,5337/6472,2
R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,3/265,117/11091,0.5327616907165558,0.8671792022053029,0.7538049895989547,7277/10382/7280,3
R-HSA-9609646,HCMV Infection,4/265,160/11091,0.5344175370326869,0.867995654100606,0.7545146993231752,7277/10382/8338/7280,4
R-HSA-397795,G-protein beta:gamma signalling,1/265,32/11091,0.539279188617574,0.8721246233127218,0.7581038508919375,695,1
R-HSA-8941326,RUNX2 regulates bone development,1/265,32/11091,0.539279188617574,0.8721246233127218,0.7581038508919375,25937,1
R-HSA-9820952,Respiratory Syncytial Virus Infection Pathway,3/265,120/11091,0.5499449784848938,0.8786412025093439,0.7637684585082624,6383/4131/2719,3
R-HSA-1839126,FGFR2 mutant receptor activation,1/265,33/11091,0.5503191574227406,0.8786412025093439,0.7637684585082624,2246,1
R-HSA-1980145,Signaling by NOTCH2,1/265,33/11091,0.5503191574227406,0.8786412025093439,0.7637684585082624,3714,1
R-HSA-4085001,Sialic acid metabolism,1/265,33/11091,0.5503191574227406,0.8786412025093439,0.7637684585082624,51046,1
R-HSA-5357956,TNFR1-induced NF-kappa-B signaling pathway,1/265,33/11091,0.5503191574227406,0.8786412025093439,0.7637684585082624,7185,1
R-HSA-5654726,Negative regulation of FGFR1 signaling,1/265,33/11091,0.5503191574227406,0.8786412025093439,0.7637684585082624,2246,1
R-HSA-9009391,Extra-nuclear estrogen signaling,2/265,77/11091,0.5527039671913196,0.8805792019658313,0.7654530856953825,2353/4318,2
R-HSA-9609507,Protein localization,4/265,164/11091,0.5540062037083533,0.8807878756631748,0.7656344775851506,6804/283927/51268/9381,4
R-HSA-5579029,Metabolic disorders of biological oxidation enzymes,1/265,34/11091,0.5610955567067859,0.8883028603021116,0.7721669600330506,4128,1
R-HSA-5654727,Negative regulation of FGFR2 signaling,1/265,34/11091,0.5610955567067859,0.8883028603021116,0.7721669600330506,2246,1
R-HSA-114604,GPVI-mediated activation cascade,1/265,35/11091,0.5716146556913844,0.8938007596962995,0.7769460691089054,6850,1
R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,1/265,35/11091,0.5716146556913844,0.8938007596962995,0.7769460691089054,1028,1
R-HSA-9006931,Signaling by Nuclear Receptors,7/265,298/11091,0.5722397034130609,0.8938007596962995,0.7769460691089054,2353/8644/4318/6387/8338/8204/1382,7
R-HSA-1483257,Phospholipid metabolism,5/265,212/11091,0.5748966714829895,0.8938007596962995,0.7769460691089054,43/5337/1103/3635/64900,5
R-HSA-168898,Toll-like Receptor Cascades,4/265,169/11091,0.5778670120417944,0.8938007596962995,0.7769460691089054,2353/6285/7096/695,4
R-HSA-390522,Striated Muscle Contraction,1/265,36/11091,0.5818825750330795,0.8938007596962995,0.7769460691089054,1756,1
R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,1/265,36/11091,0.5818825750330795,0.8938007596962995,0.7769460691089054,695,1
R-HSA-6804757,Regulation of TP53 Degradation,1/265,36/11091,0.5818825750330795,0.8938007596962995,0.7769460691089054,6446,1
R-HSA-8956319,Nucleotide catabolism,1/265,36/11091,0.5818825750330795,0.8938007596962995,0.7769460691089054,4907,1
R-HSA-9824585,Regulation of MITF-M-dependent genes involved in pigmentation,1/265,36/11091,0.5818825750330795,0.8938007596962995,0.7769460691089054,51176,1
R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,2/265,82/11091,0.5870250352528463,0.8938007596962995,0.7769460691089054,7277/10382,2
R-HSA-380287,Centrosome maturation,2/265,82/11091,0.5870250352528463,0.8938007596962995,0.7769460691089054,7277/10382,2
R-HSA-9856651,MITF-M-dependent gene expression,2/265,82/11091,0.5870250352528463,0.8938007596962995,0.7769460691089054,51176/2766,2
R-HSA-2500257,Resolution of Sister Chromatid Cohesion,3/265,127/11091,0.5885584173131659,0.8938007596962995,0.7769460691089054,7277/10382/7280,3
R-HSA-111933,Calmodulin induced events,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,5582,1
R-HSA-111997,CaM pathway,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,5582,1
R-HSA-1660661,Sphingolipid de novo biosynthesis,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,5587,1
R-HSA-168638,NOD1/2 Signaling Pathway,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,834,1
R-HSA-2129379,Molecules associated with elastic fibres,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,655,1
R-HSA-5689901,Metalloprotease DUBs,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,8338,1
R-HSA-6806003,Regulation of TP53 Expression and Degradation,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,6446,1
R-HSA-8979227,Triglyceride metabolism,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,64900,1
R-HSA-9675126,Diseases of mitotic cell cycle,1/265,37/11091,0.5919052903307941,0.8938007596962995,0.7769460691089054,1028,1
R-HSA-446203,Asparagine N-linked glycosylation,7/265,304/11091,0.5934576668989042,0.8942091974984752,0.7773011081278739,7277/57731/10382/286/51046/7280/63908,7
R-HSA-70326,Glucose metabolism,2/265,84/11091,0.6001987834400706,0.8942091974984752,0.7773011081278739,226/2026,2
R-HSA-6798695,Neutrophil degranulation,11/265,480/11091,0.6004348022753323,0.8942091974984752,0.7773011081278739,7130/718/5337/23114/4318/226/5806/64386/5799/3106/57126,11
R-HSA-111465,Apoptotic cleavage of cellular proteins,1/265,38/11091,0.6016886355508356,0.8942091974984752,0.7773011081278739,4137,1
R-HSA-5655302,Signaling by FGFR1 in disease,1/265,38/11091,0.6016886355508356,0.8942091974984752,0.7773011081278739,2246,1
R-HSA-8853884,Transcriptional Regulation by VENTX,1/265,38/11091,0.6016886355508356,0.8942091974984752,0.7773011081278739,51176,1
R-HSA-9013424,RHOV GTPase cycle,1/265,38/11091,0.6016886355508356,0.8942091974984752,0.7773011081278739,50855,1
R-HSA-9607240,FLT3 Signaling,1/265,38/11091,0.6016886355508356,0.8942091974984752,0.7773011081278739,6850,1
R-HSA-912446,Meiotic recombination,2/265,85/11091,0.6066664975143055,0.8957025284317072,0.7785992023461509,27030/8338,2
R-HSA-111996,Ca-dependent events,1/265,39/11091,0.6112383063713396,0.8957025284317072,0.7785992023461509,5582,1
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),1/265,39/11091,0.6112383063713396,0.8957025284317072,0.7785992023461509,57126,1
R-HSA-420499,Class C/3 (Metabotropic glutamate/pheromone receptors),1/265,39/11091,0.6112383063713396,0.8957025284317072,0.7785992023461509,2912,1
R-HSA-9840310,Glycosphingolipid catabolism,1/265,39/11091,0.6112383063713396,0.8957025284317072,0.7785992023461509,55512,1
R-HSA-8939211,ESR-mediated signaling,5/265,222/11091,0.6159242975415475,0.8957025284317072,0.7785992023461509,2353/4318/6387/8338/8204,5
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,3/265,133/11091,0.6199244193243895,0.8957025284317072,0.7785992023461509,718/10219/3106,3
R-HSA-1461957,Beta defensins,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,7096,1
R-HSA-1483166,Synthesis of PA,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,5337,1
R-HSA-5654741,Signaling by FGFR3,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,2246,1
R-HSA-6783310,Fanconi Anemia Pathway,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,57697,1
R-HSA-8853659,RET signaling,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,2674,1
R-HSA-9013420,RHOU GTPase cycle,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,50855,1
R-HSA-9664323,FCGR3A-mediated IL10 synthesis,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,6850,1
R-HSA-9692916,SARS-CoV-1 activates/modulates innate immune responses,1/265,40/11091,0.6205598634480312,0.8957025284317072,0.7785992023461509,834,1
R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,2/265,88/11091,0.6255936527619643,0.9009047798319048,0.7831213161752699,7277/10382,2
R-HSA-5654743,Signaling by FGFR4,1/265,41/11091,0.6296587356031547,0.9009047798319048,0.7831213161752699,2246,1
R-HSA-9717207,"Sensory perception of sweet, bitter, and umami (glutamate) taste",1/265,41/11091,0.6296587356031547,0.9009047798319048,0.7831213161752699,6326,1
R-HSA-190236,Signaling by FGFR,2/265,89/11091,0.6317444678363735,0.9009047798319048,0.7831213161752699,7049/2246,2
R-HSA-3371556,Cellular response to heat stress,2/265,89/11091,0.6317444678363735,0.9009047798319048,0.7831213161752699,9531/259217,2
R-HSA-9616222,Transcriptional regulation of granulopoiesis,2/265,89/11091,0.6317444678363735,0.9009047798319048,0.7831213161752699,51176/8338,2
R-HSA-1632852,Macroautophagy,3/265,136/11091,0.6349886487324781,0.9009047798319048,0.7831213161752699,7277/10382/7280,3
R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,2/265,90/11091,0.6378164740361582,0.9009047798319048,0.7831213161752699,51176/8338,2
R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,1/265,42/11091,0.6385402229393686,0.9009047798319048,0.7831213161752699,4035,1
R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,1/265,42/11091,0.6385402229393686,0.9009047798319048,0.7831213161752699,51176,1
R-HSA-381676,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,1/265,42/11091,0.6385402229393686,0.9009047798319048,0.7831213161752699,3745,1
R-HSA-9035034,RHOF GTPase cycle,1/265,42/11091,0.6385402229393686,0.9009047798319048,0.7831213161752699,10409,1
R-HSA-1489509,DAG and IP3 signaling,1/265,43/11091,0.6472094998803648,0.9047065263141821,0.7864260258134198,5582,1
R-HSA-432040,Vasopressin regulates renal water homeostasis via Aquaporins,1/265,43/11091,0.6472094998803648,0.9047065263141821,0.7864260258134198,358,1
R-HSA-5655253,Signaling by FGFR2 in disease,1/265,43/11091,0.6472094998803648,0.9047065263141821,0.7864260258134198,2246,1
R-HSA-111885,Opioid Signalling,2/265,92/11091,0.6497250519398131,0.9047065263141821,0.7864260258134198,5582/4988,2
R-HSA-4086400,PCP/CE pathway,2/265,92/11091,0.6497250519398131,0.9047065263141821,0.7864260258134198,50855/5582,2
R-HSA-5663220,RHO GTPases Activate Formins,3/265,140/11091,0.6544229382128974,0.9047065263141821,0.7864260258134198,7277/10382/7280,3
R-HSA-71291,Metabolism of amino acids and derivatives,8/265,367/11091,0.654634626164988,0.9047065263141821,0.7864260258134198,29958/51268/162417/445/2628/57571/1373/1735,8
R-HSA-109704,PI3K Cascade,1/265,44/11091,0.6556716181399325,0.9047065263141821,0.7864260258134198,2246,1
R-HSA-1566948,Elastic fibre formation,1/265,44/11091,0.6556716181399325,0.9047065263141821,0.7864260258134198,655,1
R-HSA-373752,Netrin-1 signaling,1/265,44/11091,0.6556716181399325,0.9047065263141821,0.7864260258134198,90249,1
R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,1/265,44/11091,0.6556716181399325,0.9047065263141821,0.7864260258134198,834,1
R-HSA-6811438,Intra-Golgi traffic,1/265,44/11091,0.6556716181399325,0.9047065263141821,0.7864260258134198,63908,1
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,2/265,94/11091,0.6613216950355438,0.9061279405355692,0.7876616056447208,8338/8013,2
R-HSA-9679506,SARS-CoV Infections,9/265,414/11091,0.6616411141713264,0.9061279405355692,0.7876616056447208,6383/2697/6850/7096/2719/834/3106/478/695,9
R-HSA-5683057,MAPK family signaling cascades,7/265,325/11091,0.6632748951739986,0.9061279405355692,0.7876616056447208,4254/57731/2902/2674/1741/4684/2246,7
R-HSA-3899300,SUMOylation of transcription cofactors,1/265,45/11091,0.6639315096211418,0.9061279405355692,0.7876616056447208,8204,1
R-HSA-445355,Smooth Muscle Contraction,1/265,45/11091,0.6639315096211418,0.9061279405355692,0.7876616056447208,8913,1
R-HSA-445989,TAK1-dependent IKK and NF-kappa-B activation,1/265,45/11091,0.6639315096211418,0.9061279405355692,0.7876616056447208,6285,1
R-HSA-373080,Class B/2 (Secretin family receptors),2/265,95/11091,0.6670038955651895,0.9079154236025543,0.7892153948168901,7432/117,2
R-HSA-8854214,TBC/RABGAPs,1/265,46/11091,0.6719939892472866,0.9079154236025543,0.7892153948168901,51560,1
R-HSA-8878159,Transcriptional regulation by RUNX3,2/265,96/11091,0.6726091935623778,0.9079154236025543,0.7892153948168901,51176/25937,2
R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,2/265,97/11091,0.6781380048193213,0.9079154236025543,0.7892153948168901,2353/6285,2
R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,2/265,97/11091,0.6781380048193213,0.9079154236025543,0.7892153948168901,2353/6285,2
R-HSA-975871,MyD88 cascade initiated on plasma membrane,2/265,97/11091,0.6781380048193213,0.9079154236025543,0.7892153948168901,2353/6285,2
R-HSA-2173789,TGF-beta receptor signaling activates SMADs,1/265,47/11091,0.6798637577261883,0.9079154236025543,0.7892153948168901,7049,1
R-HSA-6783783,Interleukin-10 signaling,1/265,47/11091,0.6798637577261883,0.9079154236025543,0.7892153948168901,3627,1
R-HSA-69231,Cyclin D associated events in G1,1/265,47/11091,0.6798637577261883,0.9079154236025543,0.7892153948168901,1028,1
R-HSA-69236,G1 Phase,1/265,47/11091,0.6798637577261883,0.9079154236025543,0.7892153948168901,1028,1
R-HSA-9024446,NR1H2 and NR1H3-mediated signaling,1/265,47/11091,0.6798637577261883,0.9079154236025543,0.7892153948168901,8204,1
R-HSA-9717189,Sensory perception of taste,1/265,47/11091,0.6798637577261883,0.9079154236025543,0.7892153948168901,6326,1
R-HSA-3858494,Beta-catenin independent WNT signaling,3/265,146/11091,0.6821698861328978,0.9079154236025543,0.7892153948168901,50855/5582/51176,3
R-HSA-5620912,Anchoring of the basal body to the plasma membrane,2/265,98/11091,0.6835907691481895,0.9079154236025543,0.7892153948168901,7277/10382,2
R-HSA-112399,IRS-mediated signalling,1/265,48/11091,0.6875454042494191,0.9079154236025543,0.7892153948168901,2246,1
R-HSA-418597,G alpha (z) signalling events,1/265,48/11091,0.6875454042494191,0.9079154236025543,0.7892153948168901,5582,1
R-HSA-5357905,Regulation of TNFR1 signaling,1/265,48/11091,0.6875454042494191,0.9079154236025543,0.7892153948168901,7185,1
R-HSA-9707616,Heme signaling,1/265,48/11091,0.6875454042494191,0.9079154236025543,0.7892153948168901,8204,1
R-HSA-15869,Metabolism of nucleotides,2/265,99/11091,0.6889679490052663,0.9079154236025543,0.7892153948168901,4907/2766,2
R-HSA-2559583,Cellular Senescence,4/265,195/11091,0.6893879080811949,0.9079154236025543,0.7892153948168901,2353/4217/8338/23043,4
R-HSA-5358351,Signaling by Hedgehog,3/265,149/11091,0.6954113970312167,0.9142471513417394,0.7947193182855826,7277/10382/7280,3
R-HSA-1461973,Defensins,1/265,50/11091,0.7023621463658936,0.9211045042411685,0.8006801471637257,7096,1
R-HSA-9612973,Autophagy,3/265,151/11091,0.7040060758348781,0.9211045042411685,0.8006801471637257,7277/10382/7280,3
R-HSA-112043,PLC beta mediated events,1/265,51/11091,0.7095058861732515,0.9211045042411685,0.8006801471637257,5582,1
R-HSA-171306,Packaging Of Telomere Ends,1/265,51/11091,0.7095058861732515,0.9211045042411685,0.8006801471637257,8338,1
R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,2/265,103/11091,0.7097307926129892,0.9211045042411685,0.8006801471637257,2353/6285,2
R-HSA-5617833,Cilium Assembly,4/265,201/11091,0.7119432995732529,0.9211045042411685,0.8006801471637257,7277/10382/57576/7280,4
R-HSA-1500931,Cell-Cell communication,3/265,153/11091,0.7124153143553735,0.9211045042411685,0.8006801471637257,50855/2318/3914,3
R-HSA-975155,MyD88 dependent cascade initiated on endosome,2/265,104/11091,0.7147376895537613,0.9211045042411685,0.8006801471637257,2353/6285,2
R-HSA-2428928,IRS-related events triggered by IGF1R,1/265,52/11091,0.7164787974199985,0.9211045042411685,0.8006801471637257,2246,1
R-HSA-2980766,Nuclear Envelope Breakdown,1/265,52/11091,0.7164787974199985,0.9211045042411685,0.8006801471637257,64900,1
R-HSA-75153,Apoptotic execution phase,1/265,52/11091,0.7164787974199985,0.9211045042411685,0.8006801471637257,4137,1
R-HSA-1474165,Reproduction,3/265,154/11091,0.7165507114110153,0.9211045042411685,0.8006801471637257,27030/8338/7852,3
R-HSA-73887,Death Receptor Signaling,3/265,154/11091,0.7165507114110153,0.9211045042411685,0.8006801471637257,55512/84894/7185,3
R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,2/265,105/11091,0.7196721815354197,0.9234749339962957,0.8027406691093222,2353/6285,2
R-HSA-1660499,Synthesis of PIPs at the plasma membrane,1/265,53/11091,0.7232849500319833,0.9234749339962957,0.8027406691093222,3635,1
R-HSA-2428924,IGF1R signaling cascade,1/265,53/11091,0.7232849500319833,0.9234749339962957,0.8027406691093222,2246,1
R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,2/265,106/11091,0.7245348551300724,0.9234749339962957,0.8027406691093222,2353/6285,2
R-HSA-211945,Phase I - Functionalization of compounds,2/265,106/11091,0.7245348551300724,0.9234749339962957,0.8027406691093222,4128/4129,2
R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),1/265,54/11091,0.7299283173305452,0.9245115347151543,0.8036417456020589,2246,1
R-HSA-74751,Insulin receptor signalling cascade,1/265,54/11091,0.7299283173305452,0.9245115347151543,0.8036417456020589,2246,1
R-HSA-418555,G alpha (s) signalling events,3/265,158/11091,0.732634381631404,0.9245115347151543,0.8036417456020589,5138/7432/117,3
R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,2/265,108/11091,0.7340471592850516,0.9245115347151543,0.8036417456020589,2353/6285,2
R-HSA-1912422,Pre-NOTCH Expression and Processing,2/265,108/11091,0.7340471592850516,0.9245115347151543,0.8036417456020589,3955/8338,2
R-HSA-110330,Recognition and association of DNA glycosylase with site containing an affected purine,1/265,55/11091,0.7364127783169913,0.9245115347151543,0.8036417456020589,8338,1
R-HSA-110331,Cleavage of the damaged purine,1/265,55/11091,0.7364127783169913,0.9245115347151543,0.8036417456020589,8338,1
R-HSA-73927,Depurination,1/265,55/11091,0.7364127783169913,0.9245115347151543,0.8036417456020589,8338,1
R-HSA-9013409,RHOJ GTPase cycle,1/265,55/11091,0.7364127783169913,0.9245115347151543,0.8036417456020589,2697,1
R-HSA-112040,G-protein mediated events,1/265,56/11091,0.7427421199032542,0.9266110591471627,0.8054667801377213,5582,1
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),2/265,110/11091,0.7432795446717111,0.9266110591471627,0.8054667801377213,2353/8338,2
R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,2/265,110/11091,0.7432795446717111,0.9266110591471627,0.8054667801377213,6543/6547,2
R-HSA-977225,Amyloid fiber formation,2/265,110/11091,0.7432795446717111,0.9266110591471627,0.8054667801377213,793/8338,2
R-HSA-166166,MyD88-independent TLR4 cascade,2/265,111/11091,0.7477923594887101,0.9266110591471627,0.8054667801377213,2353/6285,2
R-HSA-937061,TRIF (TICAM1)-mediated TLR4 signaling,2/265,111/11091,0.7477923594887101,0.9266110591471627,0.8054667801377213,2353/6285,2
R-HSA-186797,Signaling by PDGF,1/265,58/11091,0.7549501450933578,0.9266110591471627,0.8054667801377213,1297,1
R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/265,58/11091,0.7549501450933578,0.9266110591471627,0.8054667801377213,3714,1
R-HSA-2644603,Signaling by NOTCH1 in Cancer,1/265,58/11091,0.7549501450933578,0.9266110591471627,0.8054667801377213,3714,1
R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/265,58/11091,0.7549501450933578,0.9266110591471627,0.8054667801377213,3714,1
R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/265,58/11091,0.7549501450933578,0.9266110591471627,0.8054667801377213,3714,1
R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/265,58/11091,0.7549501450933578,0.9266110591471627,0.8054667801377213,3714,1
R-HSA-917937,Iron uptake and transport,1/265,58/11091,0.7549501450933578,0.9266110591471627,0.8054667801377213,7018,1
R-HSA-9006925,Intracellular signaling by second messengers,6/265,310/11091,0.7553358766718228,0.9266110591471627,0.8054667801377213,4254/5582/118788/57167/6446/2246,6
R-HSA-9013406,RHOQ GTPase cycle,1/265,59/11091,0.7608359614216691,0.9318381807639987,0.8100105126741927,2697,1
R-HSA-110328,Recognition and association of DNA glycosylase with site containing an affected pyrimidine,1/265,60/11091,0.7665809279031103,0.932797504503461,0.8108444153088596,8338,1
R-HSA-110329,Cleavage of the damaged pyrimidine,1/265,60/11091,0.7665809279031103,0.932797504503461,0.8108444153088596,8338,1
R-HSA-5218859,Regulated Necrosis,1/265,60/11091,0.7665809279031103,0.932797504503461,0.8108444153088596,834,1
R-HSA-73928,Depyrimidination,1/265,60/11091,0.7665809279031103,0.932797504503461,0.8108444153088596,8338,1
R-HSA-1257604,PIP3 activates AKT signaling,5/265,268/11091,0.7720813090412367,0.9356825142094299,0.8133522414950392,4254/118788/57167/6446/2246,5
R-HSA-8943724,Regulation of PTEN gene transcription,1/265,61/11091,0.7721884026656591,0.9356825142094299,0.8133522414950392,57167,1
R-HSA-1500620,Meiosis,2/265,117/11091,0.7734635592498331,0.9356825142094299,0.8133522414950392,27030/8338,2
R-HSA-4086398,Ca2+ pathway,1/265,62/11091,0.7776616640703373,0.9356825142094299,0.8133522414950392,51176,1
R-HSA-6796648,TP53 Regulates Transcription of DNA Repair Genes,1/265,62/11091,0.7776616640703373,0.9356825142094299,0.8133522414950392,2353,1
R-HSA-73728,RNA Polymerase I Promoter Opening,1/265,62/11091,0.7776616640703373,0.9356825142094299,0.8133522414950392,8338,1
R-HSA-73929,"Base-Excision Repair, AP Site Formation",1/265,62/11091,0.7776616640703373,0.9356825142094299,0.8133522414950392,8338,1
R-HSA-1226099,Signaling by FGFR in disease,1/265,63/11091,0.7830039125988857,0.9376702138325714,0.8150800710946625,2246,1
R-HSA-446219,Synthesis of substrates in N-glycan biosythesis,1/265,63/11091,0.7830039125988857,0.9376702138325714,0.8150800710946625,51046,1
R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,1/265,64/11091,0.7882182726969358,0.9376702138325714,0.8150800710946625,3428,1
R-HSA-450294,MAP kinase activation,1/265,64/11091,0.7882182726969358,0.9376702138325714,0.8150800710946625,2353,1
R-HSA-4608870,Asymmetric localization of PCP proteins,1/265,64/11091,0.7882182726969358,0.9376702138325714,0.8150800710946625,50855,1
R-HSA-5334118,DNA methylation,1/265,64/11091,0.7882182726969358,0.9376702138325714,0.8150800710946625,8338,1
R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,2/265,121/11091,0.7892888901010875,0.9376702138325714,0.8150800710946625,8338/9935,2
R-HSA-5619507,Activation of HOX genes during differentiation,2/265,121/11091,0.7892888901010875,0.9376702138325714,0.8150800710946625,8338/9935,2
R-HSA-373755,Semaphorin interactions,1/265,65/11091,0.793307794573721,0.9394763173534459,0.8166500462996782,56896,1
R-HSA-9614085,FOXO-mediated transcription,1/265,65/11091,0.793307794573721,0.9394763173534459,0.8166500462996782,4852,1
R-HSA-195258,RHO GTPase Effectors,6/265,326/11091,0.7961051967579362,0.940016560522871,0.8171196585732124,7277/10382/3798/8338/7280/695,6
R-HSA-8978868,Fatty acid metabolism,3/265,176/11091,0.7962640279961022,0.940016560522871,0.8171196585732124,283927/5730/8644,3
R-HSA-5625886,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,1/265,66/11091,0.7982754559593518,0.9409140170555369,0.8178997824628899,8338,1
R-HSA-427359,SIRT1 negatively regulates rRNA expression,1/265,67/11091,0.8031241638206461,0.9436708924892592,0.8202962265339165,8338,1
R-HSA-9670095,Inhibition of DNA recombination at telomere,1/265,67/11091,0.8031241638206461,0.9436708924892592,0.8202962265339165,8338,1
R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,2/265,126/11091,0.8076991200234521,0.9448029246336624,0.8212802578352526,7096/3106,2
R-HSA-204005,COPII-mediated vesicle transport,1/265,68/11091,0.807856756036496,0.9448029246336624,0.8212802578352526,63908,1
R-HSA-68616,Assembly of the ORC complex at the origin of replication,1/265,68/11091,0.807856756036496,0.9448029246336624,0.8212802578352526,8338,1
R-HSA-388841,Costimulation by the CD28 family,1/265,69/11091,0.8124760030337136,0.9487297426729078,0.8246936872898597,29126,1
R-HSA-9821002,Chromatin modifications during the maternal to zygotic transition (MZT),1/265,70/11091,0.8169846093842912,0.9525153895457162,0.8279844021666991,8338,1
R-HSA-212300,PRC2 methylates histones and DNA,1/265,72/11091,0.8256803984800682,0.958197005643536,0.8329232089930515,8338,1
R-HSA-448424,Interleukin-17 signaling,1/265,72/11091,0.8256803984800682,0.958197005643536,0.8329232089930515,2353,1
R-HSA-9710421,Defective pyroptosis,1/265,72/11091,0.8256803984800682,0.958197005643536,0.8329232089930515,8338,1
R-HSA-2299718,Condensation of Prophase Chromosomes,1/265,73/11091,0.8298726749482397,0.9586240423365227,0.8332944153009247,8338,1
R-HSA-5654738,Signaling by FGFR2,1/265,73/11091,0.8298726749482397,0.9586240423365227,0.8332944153009247,2246,1
R-HSA-9824439,Bacterial Infection Pathways,1/265,73/11091,0.8298726749482397,0.9586240423365227,0.8332944153009247,6804,1
R-HSA-2467813,Separation of Sister Chromatids,3/265,190/11091,0.8365913296355837,0.9649028832606732,0.8387523663282168,7277/10382/7280,3
R-HSA-427389,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,1/265,75/11091,0.8379582750668393,0.9649994224353188,0.8388362840598166,8338,1
R-HSA-9694516,SARS-CoV-2 Infection,5/265,299/11091,0.8466351148537005,0.9693570517516694,0.8426242009207542,6383/2697/7096/2719/3106,5
R-HSA-1221632,Meiotic synapsis,1/265,78/11091,0.8493744153197926,0.9693570517516694,0.8426242009207542,8338,1
R-HSA-3214858,RMTs methylate histone arginines,1/265,78/11091,0.8493744153197926,0.9693570517516694,0.8426242009207542,8338,1
R-HSA-446193,"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",1/265,78/11091,0.8493744153197926,0.9693570517516694,0.8426242009207542,51046,1
R-HSA-73886,Chromosome Maintenance,2/265,140/11091,0.8518600175282034,0.9693570517516694,0.8426242009207542,55320/8338,2
R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,1/265,79/11091,0.8529988391770753,0.9693570517516694,0.8426242009207542,8338,1
R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,1/265,79/11091,0.8529988391770753,0.9693570517516694,0.8426242009207542,6850,1
R-HSA-9664433,Leishmania parasite growth and survival,1/265,79/11091,0.8529988391770753,0.9693570517516694,0.8426242009207542,6850,1
R-HSA-69275,G2/M Transition,3/265,197/11091,0.8540529142043021,0.9693570517516694,0.8426242009207542,7277/10382/7280,3
R-HSA-68875,Mitotic Prophase,2/265,141/11091,0.8546326134459532,0.9693570517516694,0.8426242009207542,8338/64900,2
R-HSA-416482,G alpha (12/13) signalling events,1/265,80/11091,0.8565363716523818,0.9700532401846252,0.8432293703172624,695,1
R-HSA-453274,Mitotic G2-G2/M phases,3/265,199/11091,0.8587346230611225,0.9704723155262107,0.8435936561335062,7277/10382/7280,3
R-HSA-5621481,C-type lectin receptors (CLRs),2/265,143/11091,0.860036677177946,0.9704723155262107,0.8435936561335062,6850/4585,2
R-HSA-168928,DDX58/IFIH1-mediated induction of interferon-alpha/beta,1/265,82/11091,0.8633590147433975,0.9704723155262107,0.8435936561335062,6285,1
R-HSA-2871837,FCERI mediated NF-kB activation,1/265,82/11091,0.8633590147433975,0.9704723155262107,0.8435936561335062,10235,1
R-HSA-74752,Signaling by Insulin receptor,1/265,82/11091,0.8633590147433975,0.9704723155262107,0.8435936561335062,2246,1
R-HSA-195253,Degradation of beta-catenin by the destruction complex,1/265,83/11091,0.8666481292036572,0.9710046118258305,0.8440563605036965,51176,1
R-HSA-425366,"Transport of bile salts and organic acids, metal ions and amine compounds",1/265,83/11091,0.8666481292036572,0.9710046118258305,0.8440563605036965,6570,1
R-HSA-9705683,SARS-CoV-2-host interactions,3/265,203/11091,0.8677062488656357,0.9710046118258305,0.8440563605036965,2697/7096/3106,3
R-HSA-1483255,PI Metabolism,1/265,84/11091,0.8698583622851462,0.9719665504285735,0.84489253613682,3635,1
R-HSA-68877,Mitotic Prometaphase,3/265,205/11091,0.8720016807330417,0.9729158218267766,0.8457177006640935,7277/10382/7280,3
R-HSA-421270,Cell-cell junction organization,1/265,88/11091,0.8819475098215079,0.9800059258592463,0.851880851005868,50855,1
R-HSA-446652,Interleukin-1 family signaling,2/265,153/11091,0.8844038048291791,0.9800059258592463,0.851880851005868,6285/834,2
R-HSA-5250924,B-WICH complex positively regulates rRNA expression,1/265,90/11091,0.8875657178051357,0.9800059258592463,0.851880851005868,8338,1
R-HSA-73772,RNA Polymerase I Promoter Escape,1/265,90/11091,0.8875657178051357,0.9800059258592463,0.851880851005868,8338,1
R-HSA-8876198,RAB GEFs exchange GTP for GDP on RABs,1/265,90/11091,0.8875657178051357,0.9800059258592463,0.851880851005868,51560,1
R-HSA-5357801,Programmed Cell Death,3/265,213/11091,0.8879780101224071,0.9800059258592463,0.851880851005868,4137/834/90249,3
R-HSA-8957322,Metabolism of steroids,2/265,155/11091,0.8887819699946888,0.9800059258592463,0.851880851005868,8644/1645,2
R-HSA-9013148,CDC42 GTPase cycle,2/265,155/11091,0.8887819699946888,0.9800059258592463,0.851880851005868,50855/5337,2
R-HSA-73884,Base Excision Repair,1/265,91/11091,0.8902741156582072,0.9802139604318768,0.852061687329501,8338,1
R-HSA-163125,Post-translational modification: synthesis of GPI-anchored proteins,1/265,92/11091,0.8929175119628049,0.980253969337269,0.8520964655073406,51299,1
R-HSA-1912408,Pre-NOTCH Transcription and Translation,1/265,92/11091,0.8929175119628049,0.980253969337269,0.8520964655073406,8338,1
R-HSA-3214815,HDACs deacetylate histones,1/265,94/11091,0.8980154799768956,0.9829805545016382,0.8544665794310153,8338,1
R-HSA-5625740,RHO GTPases activate PKNs,1/265,94/11091,0.8980154799768956,0.9829805545016382,0.8544665794310153,8338,1
R-HSA-6803157,Antimicrobial peptides,1/265,95/11091,0.9004730500238287,0.9842379849097662,0.8555596145422241,7096,1
R-HSA-9692914,SARS-CoV-1-host interactions,1/265,96/11091,0.9028716169339492,0.9854273671035266,0.8565934980001261,834,1
R-HSA-193704,p75 NTR receptor-mediated signalling,1/265,97/11091,0.9052125920601433,0.9861820947211858,0.8572495532220835,84894,1
R-HSA-202424,Downstream TCR signaling,1/265,98/11091,0.9074973531210913,0.9861820947211858,0.8572495532220835,3635,1
R-HSA-9837999,Mitochondrial protein degradation,1/265,98/11091,0.9074973531210913,0.9861820947211858,0.8572495532220835,6472,1
R-HSA-5607764,CLEC7A (Dectin-1) signaling,1/265,101/11091,0.9140276412240826,0.9906156869817493,0.8611035017016606,6850,1
R-HSA-5689603,UCH proteinases,1/265,102/11091,0.9161006780826466,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-9645723,Diseases of programmed cell death,1/265,104/11091,0.9200985357752783,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-5250913,Positive epigenetic regulation of rRNA expression,1/265,105/11091,0.922025712258354,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-5578749,Transcriptional regulation by small RNAs,1/265,105/11091,0.922025712258354,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-68882,Mitotic Anaphase,3/265,235/11091,0.9231286172331602,0.9906156869817493,0.8611035017016606,7277/10382/7280,3
R-HSA-427413,NoRC negatively regulates rRNA expression,1/265,106/11091,0.9239065775643376,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-2555396,Mitotic Metaphase and Anaphase,3/265,236/11091,0.9244576204154216,0.9906156869817493,0.8611035017016606,7277/10382/7280,3
R-HSA-8878171,Transcriptional regulation by RUNX1,3/265,236/11091,0.9244576204154216,0.9906156869817493,0.8611035017016606,8338/5079/8013,3
R-HSA-1852241,Organelle biogenesis and maintenance,4/265,296/11091,0.9270527400090387,0.9906156869817493,0.8611035017016606,7277/10382/57576/7280,4
R-HSA-5250941,Negative epigenetic regulation of rRNA expression,1/265,109/11091,0.9292822625124724,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-73854,RNA Polymerase I Promoter Clearance,1/265,109/11091,0.9292822625124724,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-9843745,Adipogenesis,1/265,109/11091,0.9292822625124724,0.9906156869817493,0.8611035017016606,655,1
R-HSA-9748784,Drug ADME,1/265,110/11091,0.9309887094651399,0.9906156869817493,0.8611035017016606,1645,1
R-HSA-109581,Apoptosis,2/265,180/11091,0.9319706589520759,0.9906156869817493,0.8611035017016606,4137/90249,2
R-HSA-73864,RNA Polymerase I Transcription,1/265,111/11091,0.9326541308285619,0.9906156869817493,0.8611035017016606,8338,1
R-HSA-157579,Telomere Maintenance,1/265,112/11091,0.9342795092739563,0.9909424414302046,0.8613875365735683,8338,1
R-HSA-9013149,RAC1 GTPase cycle,2/265,185/11091,0.9384517718610824,0.9918378365987702,0.8621658685999949,50855/5337,2
R-HSA-9020702,Interleukin-1 signaling,1/265,115/11091,0.9389248653929393,0.9918378365987702,0.8621658685999949,6285,1
R-HSA-425407,SLC-mediated transmembrane transport,3/265,249/11091,0.9399245449466461,0.9918378365987702,0.8621658685999949,6543/6547/6570,3
R-HSA-9610379,HCMV Late Events,1/265,116/11091,0.9403994381581425,0.9918378365987702,0.8621658685999949,8338,1
R-HSA-9816359,Maternal to zygotic transition (MZT),1/265,117/11091,0.9418385405625246,0.9919644012647318,0.8622758863177471,8338,1
R-HSA-202403,TCR signaling,1/265,120/11091,0.9459514253419146,0.9935132288507259,0.863622221607364,3635,1
R-HSA-8878166,Transcriptional regulation by RUNX2,1/265,120/11091,0.9459514253419146,0.9935132288507259,0.863622221607364,25937,1
R-HSA-9007101,Rab regulation of trafficking,1/265,124/11091,0.9509879959106191,0.9974100040791989,0.8670095360206923,51560,1
R-HSA-6809371,Formation of the cornified envelope,1/265,129/11091,0.9566311238070568,0.9999271983472602,0.8691976346215686,5318,1
R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,1/265,129/11091,0.9566311238070568,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-195721,Signaling by WNT,4/265,331/11091,0.9588674584802432,0.9999271983472602,0.8691976346215686,50855/5582/51176/8338,4
R-HSA-211000,Gene Silencing by RNA,1/265,137/11091,0.9643443581184519,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-6807070,PTEN Regulation,1/265,140/11091,0.9668702368285079,0.9999271983472602,0.8691976346215686,57167,1
R-HSA-3214847,HATs acetylate histones,1/265,141/11091,0.9676719341383833,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-68867,Assembly of the pre-replicative complex,1/265,141/11091,0.9676719341383833,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-9678108,SARS-CoV-1 Infection,1/265,142/11091,0.9684543028555823,0.9999271983472602,0.8691976346215686,834,1
R-HSA-376176,Signaling by ROBO receptors,2/265,219/11091,0.9692612541616138,0.9999271983472602,0.8691976346215686,6387/7852,2
R-HSA-211859,Biological oxidations,2/265,222/11091,0.9711173161044626,0.9999271983472602,0.8691976346215686,4128/4129,2
R-HSA-8980692,RHOA GTPase cycle,1/265,147/11091,0.9720920840481942,0.9999271983472602,0.8691976346215686,5337,1
R-HSA-162587,HIV Life Cycle,1/265,149/11091,0.9734273158258633,0.9999271983472602,0.8691976346215686,7852,1
R-HSA-453279,Mitotic G1 phase and G1/S transition,1/265,149/11091,0.9734273158258633,0.9999271983472602,0.8691976346215686,1028,1
R-HSA-68886,M Phase,5/265,417/11091,0.9735091618547529,0.9999271983472602,0.8691976346215686,7277/10382/8338/64900/7280,5
R-HSA-201681,TCF dependent signaling in response to WNT,2/265,232/11091,0.9765571822166821,0.9999271983472602,0.8691976346215686,51176/8338,2
R-HSA-69002,DNA Replication Pre-Initiation,1/265,158/11091,0.9786905258016728,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-5633007,Regulation of TP53 Activity,1/265,160/11091,0.9797110736885075,0.9999271983472602,0.8691976346215686,6446,1
R-HSA-983169,Class I MHC mediated antigen processing & presentation,4/265,381/11091,0.9826834920185523,0.9999271983472602,0.8691976346215686,7096/3106/55070/695,4
R-HSA-9012999,RHO GTPase cycle,5/265,449/11091,0.9844009633590425,0.9999271983472602,0.8691976346215686,50855/2697/5337/10409/6472,5
R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,1/265,183/11091,0.9884689798068492,0.9999271983472602,0.8691976346215686,8204,1
R-HSA-69306,DNA Replication,1/265,186/11091,0.9892892087074856,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-212165,Epigenetic regulation of gene expression,1/265,187/11091,0.989549489284516,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-2990846,SUMOylation,1/265,189/11091,0.990051297255359,0.9999271983472602,0.8691976346215686,8204,1
R-HSA-3700989,Transcriptional Regulation by TP53,3/265,362/11091,0.9929338753103518,0.9999271983472602,0.8691976346215686,2353/834/6446,3
R-HSA-6805567,Keratinization,1/265,215/11091,0.9947569871564811,0.9999271983472602,0.8691976346215686,5318,1
R-HSA-5689880,Ub-specific processing proteases,1/265,219/11091,0.9952496741713852,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,4/265,459/11091,0.9958890980260994,0.9999271983472602,0.8691976346215686,4254/118788/3714/2246,4
R-HSA-162906,HIV Infection,1/265,231/11091,0.9964677211081951,0.9999271983472602,0.8691976346215686,7852,1
R-HSA-73894,DNA Repair,2/265,335/11091,0.9974718212123889,0.9999271983472602,0.8691976346215686,57697/8338,2
R-HSA-3247509,Chromatin modifying enzymes,1/265,270/11091,0.9986544918459028,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-4839726,Chromatin organization,1/265,270/11091,0.9986544918459028,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-5688426,Deubiquitination,1/265,297/11091,0.9993116716094981,0.9999271983472602,0.8691976346215686,8338,1
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,1/265,309/11091,0.9994892770863952,0.9999271983472602,0.8691976346215686,55070,1
R-HSA-9752946,Expression and translocation of olfactory receptors,1/265,379/11091,0.9999110385603622,0.9999271983472602,0.8691976346215686,65055,1
R-HSA-381753,Olfactory Signaling Pathway,1/265,387/11091,0.9999271983472602,0.9999271983472602,0.8691976346215686,65055,1
